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ABSTRACT 
REGULATION OF SYSTEM XC- AND ITS CONTRIBUTION TO CELL DEATH 
 
 
XiaoQian Liu, B.S. 
 
Marquette University, 2012 
 
 
The main focus of the studies in this thesis involves examining the role of 
cystine/glutamate exchange (system xC-) in neuronal death in primary cortical cell 
culture, with an emphasis on how glial function affects neuronal cell death.  System xC- is 
a sodium-independent transporter that mediates cystine uptake and glutamate release.  It 
accounts for most of the cystine uptake in astrocytes in mature cultures, providing the 
rate limiting substrate for synthesis of the main endogenous antioxidant glutathione.  The 
glutamate released by system xC- may lead to excessive extracellular glutamate and cause 
excitotoxicity.   
β-N-methylamino-L-alanine (BMAA) is a non-protein amino acid that may be 
involved in neurodegenerative diseases.  We found that BMAA induced oxidative stress 
by competing with cystine at system xC- leading to depletion of glutathione.  BMAA also 
drives system xC- mediated glutamate release, which may contribute to its induction of 
excitotoxicity.   
Fibroblast growth factor-2 (FGF-2) is involved in multiple processes in the central 
nervous system, including plasticity, neurogenesis, differentiation, and neuronal survival.  
Also, alterations in FGF-2 and its signaling have been implicated in neurodegenerative 
diseases and psychiatric disorders.  We found that FGF-2 greatly increased cystine uptake 
through system xC- in astrocyte-enriched primary cultures, but not in neuronal or 
microglial cultures.  Our data showed that FGF-2 increased cystine uptake by 
upregulating system xC- by acting on FGFR1, and signaling through the PI3K/Akt and 
MEK/ERK pathways.   
FGF-2 treatment for 48 hours caused significant neuronal death only in mixed 
neuronal and glial cultures, but not in neuronal-enriched or astrocyte-enriched cultures.  
Blocking system xC-, or AMPA/kainate receptors, eliminated the neuronal death induced 
by FGF-2 treatment.  Therefore, it is likely that 48 hour FGF-2 treatment induces AMPA 
receptor mediated toxicity through increased glutamate release from astrocytes due to 
increased system xC- function.  However, we cannot exclude the possibility that FGF-2 
treatment sensitizes the neurons to normal system xC- mediated glutamate release.   
Together the results indicate that 1) competitive substrates of system xC-, such as 
BMAA, that do not lead to glutathione production are particularly toxic; and 2) 
upregulation of system xC- on astrocytes may be toxic to surrounding neurons.   
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CHAPTER I 
 
 
 
 
GENERAL INTRODUCTION  
2 
OVERVIEW 
The brain is an extremely complex organ with complicated and specific 
interactions between multiple cell types and regions.  However, neuroscience research 
has historically focused primarily on neurons.  Glial cells have been traditionally 
considered as merely supporting cells.  In the last couple of decades, as our knowledge of 
the glial cells has dramatically expanded, we now know that the function of glial cells 
extends far beyond just supporting neurons.  Growing evidence suggests that neuronal 
and glial cells communicate through neurotransmitters, neuromodulators, and growth 
factors, and this bidirectional communication is critical for normal function of the brain.   
The aim of this thesis is to explore the interaction between neurons and glia, and 
how that interaction regulates neuronal fate, with a particular emphasis on the 
involvement of the cystine/glutamate antiporter (system xC-) (Fig. 1.1).  System xC- is 
mainly expressed on astrocytes and it is the main route of cystine uptake in these cells.  
This cystine uptake is the critical step in synthesizing the major antioxidant glutathione.  
Astrocytes then release glutathione, and other cysteine containing molecules, to supply 
neurons with cysteine for them to produce glutathione.  With every molecule of cystine 
uptake into the astrocytes, one molecule of glutamate is exchanged out of the cell.  This 
extrasynaptic, nonvesicular, release of glutamate not only serves to regulate synaptic 
function, but also when excessive, can over-activate glutamatergic receptors on the 
neurons to cause excitotoxicity.  Both oxidative stress and excitotoxicity have been 
implicated in various neurodegenerative diseases, as well as psychiatric disorders.  Thus, 
it is possible that system xC- plays a role in these diseases.   
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FIGURE 1.1.  Schematic diagram illustrating the function of system xC- and the 
interaction between neuron and astrocyte. 
C: cysteine, CC: cystine, Glu: glutamate, GSH: glutathione, EAAT: excitatory amino acid 
transporter 
 
 
Several pathways that are involved in system xC- regulation have been identified.  
However, the effects of changing system xC- function are not well understood.  Since 
targeting system xC- as a treatment for various brain disorders is being considered, it is 
very important to achieve a full understanding of system xC- function and regulation, as 
well as the consequences of changing its activity.   
 
4 
GLUTAMATE NEUROTRANSMISSION 
Glutamate is the most important excitatory neurotransmitter in the brain (Fonnum, 
1984).  It is also a precursor for the most important inhibitory neurotransmitter GABA 
(Petroff, 2002; Schousboe and Waagepetersen, 2007), and is a component of glutathione,   
one of the major antioxidants in the brain (Meister and Anderson, 1983; Dringen et al., 
2000).  Glutathione can be synthesized de novo from glucose in astrocytes via the Krebs 
cycle, leading to the release of glutamine from astrocytes, which is taken up by neurons 
and hydrolyzed into glutamate by glutaminase (Erecińska and Silver, 1990).  Glutamate 
can activate a large family of receptors existing on neurons and astrocytes leading to 
signal transmission.   
 
Glutamate receptors 
Glutamate signal transmission is mediated by release of glutamate and activation 
of various glutamatergic receptors.  Generally, as illustrated in Fig. 1.2, glutamatergic 
receptors can be divided into ionotropic receptors and metabotropic receptors.  Ionotropic 
receptors include N-methyl-D-Aspartate (NMDA) receptors and 2-amino-3-(5-methyl-3-
oxo-1,2- oxazol-4-yl)propanoic acid (AMPA)/kainate receptors, while metabotropic 
glutamate receptors (mGluRs) can be further divided into three subgroups.  Specific 
receptors and their properties are briefly described below (for a detailed review see 
(Dingledine et al., 1999)).   
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FIGURE 1.2.  Glutamate receptor subtypes 
(From (Niciu et al., 2012)) 
 
AMPA/Kainate receptors 
AMPA receptors are another family of glutamatergic receptors that are 
characterized by low affinity (EC50 ~ 500 µM) (Lomeli et al., 1994; Mosbacher et al., 
1994; Schoepfer et al., 1994).  AMPA receptors are heterotetrameric receptors  composed 
of four subunits (GluR1-4) (Alt et al., 2004).  Unlike the other GluRs, GluR2 has a Q/R 
site (uncharged glutamine/positively charged arginine) located in the pore of the channel.  
Physiologically almost all of the GluR2 subunits are edited to the R form, which makes 
the receptor impermeable to calcium (Jonas et al., 1994; Petroff, 2002; Schousboe and 
Waagepetersen, 2007).  Therefore, while all AMPA receptors are permeable to sodium 
and potassium, GluR2 lacking AMPA receptors are also calcium permeable (Meister and 
Anderson, 1983; Dringen et al., 2000; Clem and Barth, 2006), which awards these 
intriguing features of ionotropic glutamate receptors is their diversity of
channel properties based on subunit composition and expression proﬁle
in the mammalian brain.
5.1.1. NMDA receptors
NMDA receptors have the highest afﬁnity for glutamate (EC50 1 μM).
Three families of NMDA receptor subunits have been identiﬁed: (1)
NR1, (2) NR2A-D and (3) NR3A-B. Via in situ hybridization studies, NR1
expression appears to be ubiquitous and obligatory in the brain; it is
critical for neurodevelopment, as NR1 knockout mice die shortly after
birth due to respiratory demise. Interestingly, hippocampal CA1-speciﬁc
NR1-knockout mice display grossly normal development but impaired
long-termpotentiation (LTP), themolecular and electrophysiological cor-
relate of learning and memory in CA1 hippocampal pyramidal neur ns
and impaired spatial memory in the Morris water maze (Tsien et al.,
1996). NR2 mRNA displays differential expression and appears to be
developmentally-regulated (Monyer et al., 1994). NR2A expression pre-
dominates in the neocortex and hippocampus while NR2B is primarily
expressed in the forebrain. In contrast, NR2C and NR2D are intensely
expressed in the cerebellum and diencephalon/lower brain stem
(Nakanishi, 1992). NR3A is predominantly expressed in the neocortex
and displa s neurodevelopmental regulation; dysregulated NR3A devel-
opment has been proposed to contribute to the pathogenesis of schizo-
phrenia (Das et al., 1998; Henson et al., 2008). Finally, NR3B mRNA
expression is evident in the brainstem and alphamotor neurons of spinal
cord (Chatterton et al., 2002; Matsuda et al., 2003; Matsuda et al., 2002;
Nishi et al., 2001). More recently, NR3B has been detected in the cerebel-
lum and hippocampus (Andersson et al., 2001; Bendel et al., 2005).
NMDA receptors are among the most tightly regulated in the
mammalian brain and unique in requiring co-agonists for activation. At
least six binding sites have been identiﬁed that regulate the
probability of ion channel opening, viz., sites for two obligatory co-
ligands (glutamate and glycine), polyamines and cations (Mg2+, Zn2+
and H+). NMDA receptor ligands are short-chain dicarboxlic amino
acids (NMDA, glutamate, aspartate, etc.). Glutamate, the most potent
neurochemical agonist identiﬁed in the CNS, and several competitive
antagonists of the NMDA receptor including D-2-amino-5-phosphono-
pentanoic acid (D-AP5) and 3-(2-carboxypiperazin-4-yl)1-propeny-1-
phosphonic acid (2R-CPPene) bind to the NR2 subunit of the tetrameric
receptor complex. In contrast, glycine binds to a site on the NR1 subunit
(Dingledine et al., 1999; Kleckner and Dingledine, 1988). The glycine-
binding site on the NR1 subunit has gained clinical signiﬁcance due to
D-cycloserine's binding at the same glycineB site. D-cycloserine is a par-
tial agonist that has beenproposed as a novel neuromodulatory agent to
enhance the efﬁcacy of evidence-based psychotherapies like exposure
and response prevention in anxiety disorders (Danysz and Parsons,
1998; Krystal et al., 2009; Sheinin et al., 2001). Glycine transport re-
quires the activity of speciﬁc glycine transporters (GlyT). Two such
transporters have been identiﬁed to date, GlyT1 andGlyT2. Recent stud-
ies suggest GlyT inhibitorsmayprovide an efﬁcacious augmenting strat-
egy in treatment-refractory schizophrenia (Lane et al., 2006; Lane et al.,
2010).
Extracellular Mg2+ acts as an open-channel, voltage-dependent
“pore blocker” to preclude cation ﬂux (Nowak et al., 1984). Interestingly,
Zn2+, while also a divalent cation, does not block the pore of the NMDA
receptor. Instead, Zn2+ is an important allosteric modulator of some glu-
tamate receptors and colocalizes to synaptic vesicles and is co-released
with glutamate in select populations of synaptic vesicles, which possibly
provides an additionalmechanism to regulate glutamate receptor activa-
tion. Several additional NMDA receptor antagonists also exert their inﬂu-
ence in an analogous voltage-dependent manner, e.g. phencyclidine
(PCP), ketamine and MK-801. These noncompetitive antagonists have
recently garnered signiﬁcant attention both for their psychotomimetic
(Balla et al., 2001; Javitt, 2007; Javitt et al., 2004; Krystal et al., 1994;
Moghaddam and Adams, 1998; Patil et al., 2007; Umbricht et al., 2000)
and rapidly-acting antidepressant-like properties (aan het Rot et al.,
2010; Berman et al., 2000; Diazgranados et al., 2010; Mathew et al.,
2009; Price et al., 2009; Valentine et al., 2011; Zarate et al., 2006).
Hydrogen ions (H+) are also critical endogenous allosteric modula-
tors of glutamate receptors. At physiological pH, the presence of H+
decreases the frequency of channel opening due to H+ binding to
NR2B. The polyamine regulatory sites of ionotropic glutamate receptors
also play an important pH-dependent modulatory role. The binding of
polyamines (spermine, spermidine) relieves the H+-mediated block
and increases cation ﬂux; however, the effect of polyamines reverses
at higher concentrations (Traynelis et al., 1995). These pH-dependent
Fig. 2. Glutamate receptor subtypes.
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receptors the important property of increasing intracellular calcium levels when they are 
activated (Erecińska and Silver, 1990; Schneggenburger et al., 1993).   
Kainate receptors are tetramers of GluR5, GluR6, GluR7, KA1, and KA2 
(Dingledine et al., 1999).  Similar to AMPA receptors, they are ion channels that are 
permeable to sodium and potassium (Dingledine et al., 1999; Niciu et al., 2012).  
However, the functions of kainate receptors are not well defined.   
 
NMDA receptors 
NMDA receptors are another important ionotropic receptor subtype that are 
usually heteromers of GluN1 and GluN2 (GluN2A, GluN2B) subunits in mature brain 
(Béhé et al., 1995; Premkumar and Auerbach, 1997).  Compared to AMPA receptors, 
NMDA receptors are characterized by a high affinity (EC50 ~1 µM) for glutamate 
(Patneau and Mayer, 1990; Burnashev et al., 1995).  However, under physiological 
conditions, they are normally blocked by magnesium at negative membrane potential 
(Nowak et al., 1984).  During normal synaptic activity, AMPA receptors must be 
activated first to depolarize the cell membrane, which removes the magnesium block 
(Nowak et al., 1984; Dingledine et al., 1999).  NMDA receptor activation also requires 
binding of a co-agonist, such as glycine or D-serine (Johnson and Ascher, 1987; Schell et 
al., 1995).  NMDA receptors are nonspecific cation channels that are permeable to 
sodium, potassium, and calcium (Grienberger and Konnerth, 2012), with the permeability 
to calcium distinguishing them from most AMPA/Kainate receptors.   
 
7 
mGluRs  
mGluRs are G-protein coupled receptors that exist on neurons and glial cells 
(Conn and Pin, 1997; Ferraguti and Shigemoto, 2006; Kim et al., 2008).  Like all G-
protein coupled receptors, mGluRs have 7 transmembrane spanning domains, an agonist 
binding domain (N-terminus), as well as an intracellular domain (C-terminus) that 
couples to different G-proteins (Niciu et al., 2012).  To date, there are 8 known family 
members as illustrated in Fig. 1.2: mGluR1-8.  They are divided into three subfamilies: 
Group 1 (mGluR1 and 5) that are coupled to Gq, Group II (mGluR2 and 3) and Group III 
(mGluR 4, 6, 7 and 8) that are coupled to Gi.  Activation of Gq leads to activation of 
phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphophate (PIP2) to 
secondary messengers diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), 
which then lead to the increase in intracellular free calcium levels and activation of 
calcium dependent protein kinases such as protein kinase C (PKC) (Miller et al., 1995; 
Conn and Pin, 1997).  On the other hand, activation of Gi leads to inhibition of adenylyl 
cyclase, decreased cAMP, and decreased activation of protein kinase A (PKA) (Winder 
and Conn, 1993; Niciu et al., 2012).  Group I mGluRs are mainly localized to post 
synaptic and glial membranes, while the majority of Group II mGluRs are localized to 
presynaptic membranes and provide an autoinhibition mechanism for neurotransmitter 
release.   
 
Excitotoxicity 
Although glutamate transmission is essential to normal brain function, excessive 
extracellular glutamate can cause excitotoxicity.  Excitotoxicity is typically caused by 
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over-activation of glutamatergic receptors, especially NMDA receptors due to their 
permeability to calcium and slower inactivation, leading to excessive calcium influx into 
the cells to trigger cell death (Choi, 1987).  This type of neuronal death can occur in 
conditions such as stroke, traumatic brain injury, and neurodegenerative diseases (Bains 
and Shaw, 1997; Choi, 1998).   
In certain situations, over-activation of AMPA receptors can cause excitotoxicity 
as well.  AMPA receptor over-activation by addition of AMPA, a direct agonist for 
AMPA receptors, has been shown to be toxic to oligodendrocytes (McDonald et al., 
1998).  The general AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione (NBQX) has been shown to be protective to 
oligodendrocytes in multiple sclerosis models (Pitt et al., 2000; Smith et al., 2000).  
Oligodendrocyte toxicity often appears to be mediated by calcium permeable GluR2 
lacking AMPA receptors because it is prevented by the selective antagonist 1-naphthyl 
acetyl spermine (NASPM) (Yoshioka et al., 1996; Bannerman et al., 2007).   
 
Regulation of extracellular glutamate by astrocytic glutamate transporters 
Total glutamate concentration is extremely high in the brain (10 mM) (Erecińska 
and Silver, 1990), but the extracellular glutamate concentration is very low (below 10 
µM) (Ronne-Engström et al., 1995; Baker et al., 2003; Rodriguez et al., 2012).  The 
extracellular glutamate is tightly regulated by the excitatory amino acid transporters 
(EAATs).  EAATs mediate sodium-dependent high-affinity glutamate uptake, which is 
driven by the sodium concentration gradients: for every glutamate taken up, three 
molecules of sodium enter the cell while one molecule of potassium exits the cell 
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(Barbour et al., 1988; Zerangue and Kavanaugh, 1996a).  Astrocytes with abundant 
glutamate transporters EAAT1/GLAST and EAAT2/GLT-1 activity-dependently 
ensheath glutamatergic synapses (Ventura and Harris, 1999; Witcher et al., 2010), where 
they are involved in clearing extracellular glutamate to avoid unwanted prolonged 
synaptic activation and excitotoxicity (Amara, 1992; Kanai and Hediger, 1992; Storck et 
al., 1992; Rothstein et al., 1994; 1996; Diamond and Jahr, 1997; Lehre and Danbolt, 
1998).  Glutamate taken up by astrocytes is converted into glutamine by glutamine 
synthetase.  Glutamine, in turn, can be released and taken up by neurons to synthesize 
glutamate.  This glutamate-glutamine cycle between neurons and astrocytes ensures 
signaling specificity and a fast turnover rate (Sibson et al., 1998).   
 
Synaptic and extrasynaptic compartments 
Another important function of astrocytes ensheathing synapses is that they 
spatially separate synaptic and extrasynaptic compartments of the extracellular space.  
Astrocytic EAATs provide efficient buffering and clearance of glutamate to prevent 
spillover and cross-talk between different synapses and compartments (Rothstein et al., 
1996; Asztely et al., 1997; Rusakov and Kullmann, 1998).   
Synaptic and extrasynaptic receptors seem to have different functions; the most 
studied example are the synaptic and extrasynaptic NMDA receptors.  It has become an 
increasingly accepted point of view that synaptic NMDA receptor activation is 
neuroprotective, while extrasynaptic NMDA receptor activation turns off the 
neuroprotective synaptic NMDA receptor activation and also activates intracellular 
pathways that lead to neuronal death (Hardingham et al., 2002; Riccio and Ginty, 2002; 
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Ivanov et al., 2006; Léveillé et al., 2008; Xu et al., 2009; Hardingham and Bading, 2010).  
Drugs that preferentially block extrasynaptic NMDA receptors have received particular 
attention as potential treatments for neurodisorders.  For example, memantine (MEM), 
which is an FDA approved drug for late stage Alzheimer’s disease, has been shown to 
have selectivity for extrasynaptic NMDA receptors (Lipton and Chen, 2004; Xia et al., 
2010).  MEM is an open channel blocker at NMDA receptors.  At low doses, it does not 
accumulate in the synaptic cleft to interfere with synaptic NMDA receptor mediated 
signaling.  However, it does antagonize extrasynaptic NMDA receptors that are 
hyperactive due to increased extrasynaptic glutamate levels in diseased brains (Lipton 
and Chen, 2004; Chen and Lipton, 2006; Xia et al., 2010).   
 
NEURON-GLIA INTERACTION 
Bidirectional communication between astrocytes and neuronal cells is necessary 
for the normal functioning of the nervous system during signal processing.  Some 
interactions between neurons and glia are discussed below with a focus on a typical 
glutamatergic synapse as shown in Fig. 1.3.   
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FIGURE 1.3.  A typical glutamate synapse.  
(Altered From (Niciu et al., 2012)) 
 
Regulation of astrocytes by neurons 
Physiologically, high levels of neuronal activation can cause elevated 
extracellular potassium levels, and in turn, slowly depolarize glial cells (Meeks and 
Mennerick, 2007; Sasaki et al., 2011).  Under extreme conditions, depolarization can 
spread throughout the astrocyte network and cause cortical spreading depression 
(Unekawa et al., 2012; Bogdanov et al., 2013).   
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Similar to neurons, astrocytes also express a variety of receptors to respond to 
neurotransmitter release, such as mGluRs (Venance et al., 1997), nicotinic acetylcholine 
receptors (Oikawa et al., 2005), adrenoceptor , P2 receptors of the P2X (ligand-gated 
cationic channels) and P2Y (G-protein coupled receptors) types (Butt, 2011; Köles et al., 
2011).  Most of these astrocytic receptors are Gq-protein coupled receptors.  Unlike 
neurons, astrocytes do not generate action potentials,  However, activation of these 
astrocytic Gq-protein coupled receptors by neurotransmitters can lead to elevated 
intracellular calcium levels (Venance et al., 1997; Agulhon et al., 2008).  Astrocytes also 
express some ionotropic glutamate receptors (Seifert and Steinhäuser, 2001), although 
their functional significance is largely unknown.   
 
Regulation of neurons by astrocytes  
Each astrocyte is believed to have its own territory, and within that territory, it 
may interact with 140,000, or more, synapses and neuronal processes (Benarroch, 2009).  
Therefore, individual astrocytes are potentially capable of coordinating a large amount of 
neuronal activity (Poskanzer and Yuste, 2011).  Astrocytes are also connected to each 
other through gap junctions, which allows fast chemical and electrical communication 
among astrocytes, enabling them to function as a network.  Thus, activation of a single 
astrocyte can spread to an extended surrounding area and potentially regulate the function 
of multiple neighboring neurons (Cornell-Bell et al., 1990).   
Astrocytes can also release gliotransmitters (such as glutamate, ATP, D-serine 
etc.) to regulate neuronal function and synaptic plasticity (Fellin et al., 2006; Butt, 2011; 
Parpura et al., 2012).  It is known that increased calcium levels in astrocytes, like that in 
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neurons, can trigger the fusion of vesicles containing gliotransmitters with the plasma 
membrane (Bezzi et al., 1998; 2004; Kreft et al., 2004).  Non-vesicular release of 
glutamate has also been suggested.  A recent study describes a channel mediated release 
of gliotransmitter (<900 Da), such as glutamate (Duan et al., 2003).  System xC- mediates 
a selective non-vesicular release of glutamate.  It is believed that glutamate released from 
astrocytes mainly activates the extrasynaptic pool of glutamatergic receptors (Xi et al., 
2002).   
 
Astrocyte and neuron metabolic coupling 
As the largest population of cells in the nervous system, astrocytes are crucial in 
maintaining normal glutamate transmission (Ye and Sontheimer, 2002; Huang et al., 
2004; López-Bayghen and Ortega, 2011).  Glucose is the major substrate for brain energy 
production.  Astrocytes take up glucose from their endfeet on capillaries (Magistretti and 
Pellerin, 1996; Edvinsson and Krause, 2002), metabolize it, and release L-lactate and 
pyruvate as energy sources for neurons (Dringen et al., 1993).  Metabolites from glucose 
can also be further processed to produce essential neurotransmitters such as GABA and 
glutamate (Magistretti and Pellerin, 1996).  Glutamate uptake and glucose utilization by 
astrocytes are tightly coupled as illustrated in Fig 1.4.   
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FIGURE 1.4.  Schematic representation of glutamate cycling and glucose 
metabolism coupling. 
At glutamatergic synapses, excessive extracellular glutamate is removed by a glutamate 
uptake system located primarily on astrocytes.  Glutamate is cotransported with Na+, 
resulting in an increase in the intracellular concentration of Na+ in astrocytes leading to 
activation of the Na+/K+ ATPase pump.  The pump utilizes ATP, which is provided by 
membrane-bound glycolytic enzymes.  This demand for ATP activates glycolysis in 
astrocytes, resulting in the production of lactate.  Lactate, once released can be taken up 
by neurons and serve as an energy substrate.  From (Magistretti and Pellerin, 1996) 
 
OXIDATIVE STRESS AND GLUTATHIONE IN THE BRAIN  
Oxidative stress 
Oxidative stress is an excessive accumulation of free radicals and other reactive 
oxygen species (ROS).  It can be caused by either an overproduction of free radicals or a 
deficit in their clearance.  ROS are normal products of cellular metabolism.  While some 
levels of free radical generation is normal and necessary, overwhelming amounts of free 
radicals can lead to oxidative damage to proteins, lipids and DNA, causing dysfunction of 
these molecules (Freeman and Crapo, 1982; Simonian and Coyle, 1996).  As illustrated in 
Fig. 1.5., ROS are mainly generated in the mitochondria: electrons along the electron 
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transport chain in mitochondria leak out and are accepted by oxygen resulting in 
superoxide (O2-) production (Freeman and Crapo, 1982).  There are various cellular 
defense mechanisms against ROS, such as superoxide dismutase (SOD), catalase, 
glutathione (GSH), vitamin C and vitamin E (Sies, 1997; Brigelius-Flohé and Traber, 
1999).  SOD can degrade superoxide generating hydrogen peroxide (H2O2) (Fridovich, 
1975).  H2O2 is not reactive.  However, when there are metal ions present, highly reactive 
hydroxyl radical can be generated by Fenton reaction.  In contrast, catalase can 
decompose H2O2 into water and oxygen.  The H2O2 can also be eliminated by GSH in a 
process mediated by glutathione peroxidase, generating glutathione disulfide (GSSG).  
GSSG can be reduced back to GSH by NADPH via glutathione reductase (Fig.1.5).  
Besides reducing oxidative stress, GSH can also directly conjugate to toxins, and both 
GSH and GSH conjugates can be transported out of the cells by multi-drug resistance 
proteins (Rush et al., 2012b).   
 
 
FIGURE 1.5.  Diagram illustrating the different pathways for handling O2-.   
O2-: superoxide, SOD: superoxide dismutase, GSH: glutathione, H2O2: hydrogen 
peroxide, GSSG: glutathione disulfide.   
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The brain, while only 2% of the body weight, consumes about 20% of the total 
oxygen, generating high levels of ROS (Ballatori et al., 2009), and oxidative stress has 
been shown to be a possible contributor to the damage occurring in neurodegenerative 
diseases (Simonian and Coyle, 1996; Schulz et al., 2000; Ballatori et al., 2009).   
 
GSH in the brain 
 GSH is a tripeptide consisting of the amino acids glutamate, glycine, and cysteine 
(Dringen et al., 2000).  It is the most prevalent cellular thiol in the brain, with an 
intracellular concentration of ~2.5 mM in neurons and ~ 3.8 mM in astrocytes (Bolaños 
et al., 1995; Rice and Russo-Menna, 1998).  Normally, the intracellular GSSG/GSH ratio 
is tightly regulated, with over 99% of the total cellular GSH present as the reduced form 
(Deneke and Fanburg, 1989).  The GSSG/GSH ratio is a sensitive indicator of oxidative 
stress (Rahman et al., 2005).   
 GSH is synthesized via a two-step reaction (Fig. 1.6) (Beutler, 1989; Deneke and 
Fanburg, 1989).  First, glutamate and cysteine are catalyzed to γ-glutamylcysteine by 
glutamate cysteine ligase.  Then glycine joins γ-glutamylcysteine mediated by 
glutathione synthetase.  Both steps require ATP.  Both glutamate and glycine are highly 
available in the cells, so the rate-limiting factor is cysteine.  The rate of this reaction is 
based on intracellular cysteine levels and γ-glutamylcysteine synthetase that is feedback-
regulated by GSH.  Inhibiting cystine uptake inhibits GSH synthesis because the levels of 
intracellular cysteine are dependent on cystine uptake (Bannai and Kitamura, 1980).  
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FIGURE 1.6.  GSH synthesis and cycling in the central nervous system.   
In astrocytes: 1: γ-glutamylcysteine synthetase; 2: glutathione synthetase; 3: γ -
glutamyl transpeptidase.  In Neurons: 4: dipeptidases. Glu: glutamate, CySS: cystine, 
Cys: cysteine, Gly: glycine, GSH: glutathione.  From (McBean, 2002) 
 
 Sources for cysteine seem to depend on the developmental stage and cell type in 
the central nervous system (Kranich et al., 1996).  It is believed that the sodium-
independent system xC- is the main mechanism of cystine uptake in glial cells (Lobner, 
2009), while the sodium-dependent glutamate/aspartate/cysteine transporter [System XAG 
(EAAT3/EAAC1)] is responsible for most of cysteine uptake in mature neurons 
(McBean, 2002).  Cystine will immediately be broken down by thioredoxin reductase 1 
into two cysteine molecules once it enters the cells (Arrick et al., 1985).  
In the nervous system, glial cells are important in supplying neurons with cysteine 
containing molecules, such as cysteine itself, cysteinylglycine (CysGly), or GSH 
(Dringen et al., 1999).  Extracellularly, GSH is metabolized by the ectoenzyme γ-
glutamyl transferase, which transfers the γ-glutamyl residue of GSH to different acceptor 
uptake, reduce cystine transport further
by indirectly blocking exchange.
Oxidative stress and induction of the 
xc
− exchanger
Deple ion of intracellular GSH in
fibroblasts triggers induction of xc
−,
leading to an increased rate of
Na+-independent uptake of cystine [2],
which implies that upregulation of cystine
uptake protects cells against depletion of
GSH. In addition, much recent work has
been directed towards investigating the
response of xc
−-mediated uptake of cystine
to oxidative stress. Chronic exposure of
endothelial [26] or epithelial [27] cells to
the nitric oxide donor, S-nitroso-N-acetyl-
penicillamin  (SNAP), whi h can lead to
the formation of toxic radical species,
increases xc
−-mediated cystine uptake.
Responses to oxidative stress in glioma
cells are linked to increased expression 
of xCT with no alteration in the expression
of 4F2hc [8]. xc
−-mediated transport of
glutamate in astrocytes is upregulated by
dibutyryl cAMP but, in this case, the
expression of both xCT and 4F2hc are
increased [28]. In macrophages, an
increase in intracellular GSH parallels
induction of xCT in response to bacterial
lipopolysaccharide [29].
Although upregulation of the 
xc
− exchanger will provide more cysteine
for GSH synthesis, glu amate rel ase will
also increase, potentially causing the
extracellular concentration to rise [22].
This could trigger glutamate-mediated
toxicity in certain brain pathologies.
Indeed, Ye et al. [30] reported increased
glutamate efflux by the xc
− exchanger 
in glioma cells in which the 
XAG
− transporters were mislocalized or
dysfunctional and therefore not available
to remove glutamate. However, it is
arguable that such a situation would not
happe  if XAG
− transporters were perating
normally. In other words, activation of the
xc
− exchanger would not be expected to
cause toxicity unless XAG
−-mediated
glutamate uptake was disrupted.
Convers ly, elevation of extracellula
glutamate would inhibit both avenues 
of cystine uptake into the cell, causing 
GSH levels to fall. Release of glutamate in
anoxia, for example, could damage cells
for this reason.
Concluding remarks
Much new information on the molecular
basis of cystine uptake has come to light in
recent years. Current opinion holds that
xc
−-mediated uptake of cystine might be
more important as a provider of cysteine
to synthesize GSH, particularly under
conditions of oxidative stress. However,
this view remains hypothetical until such
time as the physiological role of both 
xc
−- and XAG
−-mediated transport of 
cystine in vivo is fully resolved.
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Fig. 3. The relationship between astrocytes and neurones in glutathione (GSH) synthesis. Transport of glutamate
(G lu) and cystine (CySS) into astrocytes provides substrates for γ-glutamylcysteine synthetase (1), which catalyzes
the production of γ-glutamylcysteine. GSH synthetase (2) then catalyzes the conversion of γ-glutamylcysteine
(γ-G lu–Cys) to GSH. GSH released from astrocytes is a substrate for γ-glutamyltranspeptidase (3), which transfers 
the γ-glutamyl moiet  (γ-G lu) of GSH to an acceptor am i o acid (X). A lso shown is the net translocation of cystine into
the cell (broken line) w ith cystine as the acceptor am ino acid. The di-peptide, cysteinyl–glycine (Cys–G ly) is cleaved
into component am ino acids by an ectopeptidase (4). The identity of the glutamate and cystine transporters in this
diagram is not specified. There is uncertainty of the relative importance of cystine or cysteine as a precursor for
GSH synthesis in neurones (see text for details). Further information on other aspects of GSH metabolism in
astrocytes and neurones can be found in [19].
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amino acids leading to the formation of a γ-glutamyl containing dipeptide and a dipeptide 
CysGly.  CysGly is then either cleaved by extracellular dipeptidases to generate cysteine 
and glycine, or directly taken up by neurons.  Knocking out EAAT3 greatly reduces 
neuronal cysteine uptake and intracellular GSH levels, resulting in decreased viability of 
hippocampal neurons against H2O2 insults (Zerangue and Kavanaugh, 1996b; Chen and 
Swanson, 2003; Aoyama et al., 2006).  This suggests that EAAT3 plays a critical role in 
the ability of neurons to obtain cysteine.    
 
SYSTEM XC-  
System xC- is a sodium-independent, chloride-dependent amino acid transport 
system located on the plasma membrane.  System xC- was first characterized by Bannai 
and Kitamura in 1980 when mutual inhibition of glutamate and cystine uptake was 
described (Bannai and Kitamura, 1980).  It can transport one molecule of cystine into the 
cell in exchange for one molecule of intracellular glutamate, with Km values of ~ 80 µM 
for cystine uptake and ~ 160 µM for glutamate uptake (Sato et al., 1999).  The transport 
direction is determined by the high cytosolic glutamate levels and low cytosolic cystine 
levels.   
 
Structure of system xC- 
System xC- is a heteromeric antiporter, composed of two subunits: a light-chain 
subunit xCT and a heavy chain 4F2hc, which are linked together by one disulfide bond 
(Torrents et al., 1998; Shih et al., 2006) (Fig. 1.7.).  The 4F2hc subunit is a single 
transmembrane glycoprotein that is believed to be universally shared among the 
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heterodimer membrane transporter family: transporter systems L (Lewerenz et al., 2012; 
Bridges et al., 2012a).  Although 4F2hc by itself does not have amino acid transport 
function, it is essential to system xC- function because it brings xCT to the membrane 
(Estévez et al., 1998; Sato et al., 1999; Bassi et al., 2001).  xCT determines the substrate 
specificity and efficiency of system xC-.  It is encoded by the solute carrier family 7, 
member 11 (Slc7a11) gene (Bassi et al., 2001), which produces a 502 amino acid short 
chain protein with a predicted molecular mass of about 55.5 kDa (Sato et al., 1999).  The 
xCT subunit is highly hydrophobic and has a 12 transmembrane domain with a re-entrant 
loop and both N- and C-termini are located on the cytoplasmic side (Gasol et al., 2004).  
 
  
FIGURE 1.7.  The structure of system xC- 
System xC- is composed of a light chain xCT (shown in clear) and a heavy chain 4F2hc 
(shown in black), connected by a single disulfide bridge (shown in squares).  From (Shih 
et al., 2006).  
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Function of system xC- 
Because of the dual transport property of system xC-, it can regulate both 
intracellular GSH levels and extracellular glutamate levels.  Cystine that enters cells 
through system xC- can be broken down to cysteine to synthesize GSH, which can reduce 
free radicals or be released to regulate the redox state of the extracellular millieu (Wang 
and Cynader, 2000; Banjac et al., 2008).  System xC- has been shown to be responsible 
for 60% of extracellular glutamate in rat striatum (Baker et al., 2002).  Deleting the xCT 
gene in Drosophila causes a 50% reduction in extracellular glutamate levels (Augustin et 
al., 2007).  Extracellular glutamate released from system xC- can activate presynaptic 
mGluR2/3, which can regulate synaptic release of neurotransmitters, such as dopamine 
(Baker et al., 2002).   
Sato et al. 2005, developed and characterized xCT null mice with a partial 
deletion of the xCT gene.  These mutant mice appear healthy and fertile.  However, in 
plasma, the cystine concentration is doubled compared to wild type, while GSH levels are 
half of the wild type (Sato et al., 2005).  No difference in cysteine levels was reported.  
Microglial cells isolated from these mice showed normal levels of cystine uptake.  
However, the uptake was not blocked by glutamate and was not inducible by 
lipopolysaccharide (LPS) (Sato et al., 2005).  Fibroblasts isolated from these xCT -/- 
mice die unless exogenous 2-mercaptoethanol or N-acetylcysteine, which reduces cystine 
to cysteine, is present (Sato et al., 2005).  In xCT deficient mice, ischemia-reperfusion-
induced acute renal failure is more severe compared to wild type animals (Shibasaki et 
al., 2009).  No increased oxidative stress or brain atrophy were observed (De Bundel et 
al., 2011).  This is probably because in xCT deficient animals other cystine/cysteine 
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uptake transporters are upregulated to maintain the normal activity.  However, it is not 
possible to upregulate in these xCT deficient animals under oxidative stress to help 
increase GSH levels (Shibasaki et al., 2009).  Therefore, it appears that some degree of 
compensation for the lack of system xC- occurs, but it is not entirely effective.   
Another mutant mouse line involving altering system xC- function is the sut/sut 
mouse, which has a partial deletion of the xCT gene.  These animals show changes in fur 
color due to a deficiency in the cysteine-dependent yellow/red pigment, pheomelanin 
(Chintala et al., 2005), and a large reduction in pheomelanin is also observed in cultured 
sut/sut melanocytes.  Interestingly, sut/sut mice also exhibit prominent brain atrophy in 
the hippocampus (Shih et al., 2006).  The mechanisms resulting in different phenotypes 
of these two different mutant mouse lines require further studies.   
 
Regulation of system xC- 
Despite the involvement of system xC- in both excitotoxicity and oxidative stress, 
there is limited knowledge about its regulation.  Because xCT is specific to system xC- 
and determines specificity of its transport function, the regulation studies have been 
mainly focused on xCT regulation (Sato et al., 1999).  To date, the best-characterized 
pathways are nuclear factor eythroid 2-related factor 2 (Nrf2)-antioxidant responsive 
element (ARE) and eukaryotic initiation factor-2 (eIF2) - activating transcription factor 
(ATF) 4- amino acid response element (AARE), which are discussed in detail below, 
along with other regulatory mechanisms.   
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Nrf2-ARE pathway 
There are four ARE-like, also known as electrophile response element (EpRE)-
like, sequences in the 5’ flanking region of the mouse xCT gene (Sasaki et al., 2002), two 
of which are completely conserved in the 5’-flanking region of the human xCT gene 
(Sato et al., 2000; Sasaki et al., 2002).   
The transcription factor Nrf2-ARE pathway was first proposed by Venugopal and 
Jaiswal (Venugopal and Jaiswal, 1996), as illustrated in (Fig. 1.8).  Nrf2 is normally 
cytosolic because of keap-1 binding (Itoh et al., 1999).  However, when under oxidative 
stress, Nrf2 is freed and translocates to the nucleus and binds to ARE to activate specific 
protein transcription (Itoh et al., 1999).  ARE is a cis-acting regulatory element located in 
the promoter regions of multiple genes encoding phase II detoxification enzymes and 
antioxidant proteins (Lee and Johnson, 2004).  These proteins include heme oxygenase, 
γ-glutamylcysteine synthetase, glutamate-cysteine ligase, glutathione synthetase, 
glutathione S-transferase, glutathione reductase, multidrug resistance protein 1, as well as 
xCT (Bannai, 1984; Erickson et al., 2002; Sasaki et al., 2002).   
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FIGURE 1.8.  Nrf2-ARE pathway 
Activation of Nrf2-ARE pathways that leads to expression of ARE-driven genes, 
including xCT.  From (Lee and Johnson, 2004).   
 
Nrf2-ARE has been shown to be necessary for increased cystine uptake through 
system xC- induced by various electrophiles, such as diethyl maleate, arsenite, cadmium 
and hydroquinone, in BHK21 kidney cells (Sasaki et al., 2002).  Upregulating Nrf2 has 
been shown to increase xCT levels and protect both glial cells and neurons from 
oxidative stress insults in a phosphatidylinositol 3 kinase (PI3K)/ activate protein kinase 
B (PKB, aka, Akt) dependent manner (Shih et al., 2003; Wang et al., 2009).   
However, knocking out Nrf2 failed to affect MeHg-induced upregulation of xCT, 
which suggests Nrf2-ARE is not always involved in xCT regulation (Wang et al., 2009). 
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eIF2-ATF4-AARE pathway 
 There are two AARE-like sequences in the 5’-flanking region of the xCT gene 
(Sato et al., 2004; Lewerenz and Maher, 2009).  Amino acid response (AAR) is usually 
triggered by limited uptake of any essential amino acid (Kilberg et al., 2005).  It serves as 
a self-protective effect by globally slowing down protein production and cellular activity 
by limiting protein synthesis.  However, transcription and translation of certain proteins, 
such as basic leucine zipper and ATF4 is enhanced (Wek et al., 2006).  These proteins 
then regulate gene expression of membrane transporters and growth factors to cope with 
environmental stresses (Kilberg et al., 2005; Wek et al., 2006; Ameri and Harris, 2008; 
Kilberg et al., 2009).  It is a protective mechanism against a harmful environment, such 
as changed pH, nutrient levels, and oxidative stress (Duncan and Hershey, 1985; 1987).   
 eIF2, a heterotrimer composed of eIF2α, eIF2β, and eIF2γ, is an important 
component of the initiating complex for most of the protein synthesis (Fafournoux et al., 
2000).  The GDP in eIF2 has to be exchanged for GTP mediated by guanine nucleotide 
exchange factor eIF2B to successfully form the initiating complex (Matts and London, 
1984; Dholakia and Wahba, 1989).  Components of eIF2 can be phosphorylated, 
preventing the attached GDP from being replaced with GTP (Kilberg et al., 2009).  
Among the three, eIF2α is the most easily phosphorylated (Costa-Mattioli et al., 2007). 
The two mechanisms of eIF2B inhibition are described below, both of which can lead to 
increased ATF4 production, and then activation of AARE regulated gene transcription.    
 When there are not enough available essential amino acids in the cell, the 
excessive free tRNAs activate the general control nonrepressible protein 2 (GCN2) 
kinase, which in turn phosphorylates eIF2 (Zhang et al., 2002).  Phosphorylated eIF2 has 
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increased affinity for eIF2B, although it cannot be activated for initiating complex 
assembly.  Therefore, phosphorylated eIF2 becomes a potent competitive inhibitor for 
eIF2B (Rowlands et al., 1988; Kimball, 1999).  Normally, the intracellular eIF2 levels are 
significantly higher than eIF2B, therefore, phosphorylation of merely 30% of eIF2α is 
enough to completely block eIF2B activity (Matts and London, 1984; Duncan and 
Hershey, 1987).  Besides GCN2, there are other kinases that are sensitive to other 
stressors, and become activated leading to eIF2 phosphorylation.  These kinases include 
heme-regulated inhibitor (HRI) activated by heme-deficiency (Han et al., 2001; Lu et al., 
2001), double-stranded RNA-activated inhibitor (DAI) or dsRNA-dependent 
serine/threonine protein kinase R (PKR) activated by viral infection (Hershey, 1989; 
Proud, 2005) and PKR-like endoplasmic-reticulum (ER)-localized eIF2α kinase (PERK) 
activated by ER stress (Lu et al., 2004) (Fig. 1.9.).  All of these cellular stresses have the 
potential of activating the same pathways amino acid deprivation activate and inducing 
system xC- expression, but this theory has not yet been tested.   
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FIGURE 1.9.  Regulation of translation initiation by eIF2 phosphorylation.   
dsRNA-dependent serine/threonine protein kinase R (PKR), heme-regulated inhibitor 
(HRI), PKR-like endoplasmic-reticulum (ER)-localized eIF2α kinase (PERK), general 
control nonrepressible protein 2 (GCN2) are activated in response to various 
environmental stresses, which leads to phosphorylation of eIF2.  Phosphorylated eIF2 
inhibits eIF2B mediated guanine nucleotide exchange, in turn, globally slows down 
translation initiation, but increases ATF4 levels.  From (Wek et al., 2006) 
 
 Phosphorylation of eIF2B is another mechanism that leads to activation of AARE 
regulated gene transcription (Proud, 2005) (Fig. 1.10).  Glycogen synthetase 3β 
(GSK3β), a constitutively active kinase, can phosphorylate eIF2B, leading to the loss of 
its GEF property (Welsh and Proud, 1993) and prevents assembly of the initiation 
complex.  Hormones, mitogens, and growth factors can activate phosphatidylinositol 
3(PI3)-kinase (Welsh et al., 1998) and MEK/ERK (Kleijn and Proud, 2000; Quevedo et 
al., 2000), which can lead to phosphorylation of GSK3β to inactivate it, which removes 
the GSK3β inhibition effect on eIF2B.   
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FIGURE 1.10.  Regulation of translation initiation by eIF2B phosphorylation.   
Hormones, mitogens, and growth factors can phosphorylate glycogen synthetase 3β 
(GSK3β) through phosphatidylinositol 3(PI3)-kinase and mitogen-activated protein 
kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways. Phosphorylation of 
GSK3β removes the inhibition of eIF2B, and ensures translation initiation.   
 
 Phosphorylation of either eIF2 or phosphorylation of eIF2B can lead to global 
shut down of protein translation, however, there is increased ATF4 production, in turn, 
activates expression of AARE regulated genes.  Mutation studies showed that AARE like 
sequences in the 5’-flanking region of xCT are essential in both basal and amino acid 
deprivation induced increase in system xC- activity (Sato et al., 2004).  Deprivation of 
cystine, an essential amino acid, activates the ATF4-AARE pathway, and induces an 
increase in cystine uptake in cultured human fibroblasts after 24 hours (Bannai, 1984).  
This suggests an involvement of ATF4-AARE in system xC- regulation.  Further studies 
showed that 4F2hc is consistently induced under any amino acid deprivation, while xCT 
is only induced with certain amino acids missing (Sato et al., 2004).  This suggests that 
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the two subunits of system xC- have different regulatory mechanisms.  Decreasing 
intracellular eIF2α levels increases HT22 cells resistance to oxidative glutamate toxicity, 
while increasing intracellular eIF2α can render HT22 cells highly sensitive to glutamate 
toxicity by decreasing system xC- mediated cystine uptake, depleting GSH, and 
increasing ROS (Tan et al., 2001; Lewerenz and Maher, 2009).  This effect is mediated 
through ATF4 binding to AARE (Lewerenz and Maher, 2009).  Therefore, it appears that 
the ATF4-AARE pathway is an important regulatory mechanism for system xC-.   
 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
 
NF-κB may be another activator of xCT expression because there is a NF-κB 
binding site in the 5’-flanking region of xCT (Sato et al., 2001).  NF-κB has long been 
known to play a role in rapid response to calcium influx and harmful cellular stimuli, 
especially in the immune response (Meffert et al., 2003).  LPS is known to activate NF-
κB (Sen and Smale, 2010).  In mouse peritoneal macrophages, both xCT and 4F2hc 
mRNA increased in a time dependent manner within 12 hours of LPS treatment (Sato et 
al., 2001).  However, this LPS induced increase in xCT levels is not likely to be mediated 
through NF-κB because there was no increased nuclear NF-κB caused by the LPS 
treatment (Sato et al., 2001).  Since LPS still induces the activity of system xC- in 
macrophages prepared from Nrf2-deficient mice, it is not likely that an LPS induced 
increase in system xC- activity is mediated through the Nrf2-ARE pathway (Sato et al., 
2001). Therefore, despite an NF-κB binding site in the 5’-flanking region of xCT, there is 
no direct evidence of its role in system xC- regulation.  The mechanism of LPS inducing 
increased system xC- activity remains unclear.   
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Activator protein 1 (AP-1) 
 There are several putative AP-1 binding sites in the 5’-flanking region of xCT, 
one of them overlaps with the ARE sequence that is essential for response to electrophile 
reagent activated xCT transcription and translation (Sato et al., 2001).  AP-1 transcription 
factor mediates gene regulation in response to cytokines, growth factors, stress, and 
infections (Hess et al., 2004).  However, its role in xCT regulation has not yet been 
studied.   
 
Hypoxia inducible factor (HIF) 
 Hypoxic preconditioning, the protection against a severe hypoxic insult by an 
earlier mild hypoxic insult, increases xCT levels both transcriptionally and translationally 
in hippocampus in vivo and in mouse neuronal stem cells (Ogunrinu and Sontheimer, 
2010; Sims et al., 2012).  This is mostly mediated through HIF-1α, but since siHIF-1α 
does not completely abolish xCT upregulation in B104 mouse neuronal stem cell cultures 
after hypoxic preconditioning, the possibility of other intracellular pathways being 
involved cannot be ruled out (Sims et al., 2012).  Also, hypoxia did not induce system xC- 
function in mouse macrophage cultures (Sato et al., 2001).  Determining the mechanism 
of system xC- regulation by preconditioning, and when it occurs, requires further study.   
 
cAMP  
 In rat striatal punches, system xC- activity is decreased by 15 minutes of 
mGluR2/3 agonist treatment, and this effect is mimicked by inhibiting cAMP (Baker et 
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al., 2002).  Also, a two-fold increase in xCT mRNA levels in rat cortical astrocytes was 
observed after a 10-day incubation with N(6),2'-O-dibutyryladenosine 3':5' cyclic 
monophosphate (dbcAMP), a cAMP analog (Gochenauer and Robinson, 2001).  One 
week dbcAMP treatment potentiates buthionine sulfoximine induced increase in system 
xC- activity in rat primary astrocytes (Seib et al., 2011).  There are two consensus PKA 
phosphorylation sites on human xCT (Baker et al., 2002).  However, the exact 
intracellular pathway by which cAMP is involved in system xC- regulation is yet to be 
investigated.   
 
Growth factors 
Our lab was the first to report growth factor effects on system xC- function.  
Insulin-like growth factor 1 (IGF-1) and transforming growth factor-β (TGF-β) can 
upregulate system xC- function in dental pulp cells (Pauly et al., 2011).  We also showed 
that fibroblast growth factor-2 (FGF-2) upregulates system xC- function selectively in 
primary cortical astrocytes (Liu et al., 2011).   
 
FGF-2 RECEPTORS AND INTRACELLULAR SIGNALING PATHWAYS 
FGF-2 was the first member isolated and cloned among the FGF family of growth 
factors in the 1980s.  After decades of research, we now know FGF-2 is involved in many 
nervous system functions.  During embryonic development, FGF-2 plays an important 
role in regulating proliferation, differentiation, and migration; while in adult, FGF-2 plays 
a critical role in neuronal death, neurogenesis, learning and memory, and lesion repair 
(Reuss and Bohlen und Halbach, 2003; Eswarakumar et al., 2005).  FGF-2 expression is 
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found in both neuronal and glial cells, with glial cells as its main source (Eckenstein et 
al., 1991a; 1991b).   
FGF-2 can activate all members of the FGF receptor (FGFR) family, with FGFR1 
and FGFR2 the prominent forms present in the cerebral cortex (Reuss and Bohlen und 
Halbach, 2003).  Like any typical tyrosine kinase receptor, FGFRs are composed of an 
extracellular ligand-binding domain composed of three immunoglobulin-like domains, a 
single transmembrane domain, and an intracellular domain with catalytic protein tyrosine 
kinase activity (Mohammadi et al., 1996a).  Two molecules of FGF-2 bind to FGFRs, 
which triggers dimerization and activation of tyrosine kinase activity through 
autophosphorylation (Schlessinger et al., 1995; Mohammadi et al., 1996b).  Previous 
studies from our lab showed that in primary mouse cortical culture, FGFR1 is the most 
prevalent receptor, followed by FGFR2, and both are mostly expressed in astrocytes (Fig. 
1.11) .   
 
 
FIGURE 1.11.  Expression of mRNA for FGFR1 and FGFR2 in cerebral cortex, 
neuronal-enriched cultures, and glial-enriched cultures.  
Bps, base pairs; CTX, cerebral cortex; A, glia-enriched cortical cultures; N, neuronal-
enriched cortical cultures. Three isoforms of both FGFR1 and FGFR2 were detected.  
From (Lobner and Ali, 2002).   
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Upon activation, at the carboxy terminal tail of the FGFR, autophosphorylation on 
a tyrosine residue (Tyr766) creates a specific binding site for PLC (Mohammadi et al., 
1992; 1996a) and activates it to catalyze the hydrolysis of PIP2 to generate two secondary 
messengers: IP3 and DAG.  Also, fibroblast growth factor receptor substrate 2 (FRS2) 
constitutively docks at the juxtamembrane domain of FGFRs (Reuss and Bohlen und 
Halbach, 2003; Eswarakumar et al., 2005).  In response to FGFR activation, the docking 
proteins become tyrosine phosphorylated and recruit protein complexes and activate 
multiple intracellular signal transduction pathways, such as PI3K/Akt and mitogen-
activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) 
pathways (Kouhara et al., 1997; Ojeda et al., 2011).  The PLC activation mediated effects 
are independent from the FRS2 mediated effects  (Fig. 1.12.).   
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FIGURE 1.12.  FGF-FGFR1 intracellular signaling pathways.   
Activation of fibroblast growth factor receptor 1 (FGFR1) requires binding of two 
fibroblast growth factor-2 (FGF-2) molecules, and two independent intracellular 
pathways are activated: phospholipase C (PLC), which leads to generation of two 
secondary messengers, inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG); 
fibroblast growth factor receptor substrate 2 (FRS2) mediated activation of the mitogen-
activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) 
pathway.   
 
FGF-2 regulation, function and dysfunction in diseases 
FGF-2 in ischemia/stroke 
FGF-2 expression is upregulated rapidly in the brain after lesioning or ischemic 
insult (Frautschy et al., 1991).  Most of the FGF-2 expression is in astrocytes, with only 
some of the neurons close to the lesion core showing increased FGF-2 levels (Wei et al., 
2000).  Because of the success of FGF-2 in animal models of ischemia, it has been 
considered as a candidate for stroke treatment in humans (Ay et al., 1999; Ren and 
Finklestein, 2005).  However, clinical trials of trafermin (recombinant human FGF-2) 
administration in human acute ischemic stroke were unsuccessful.  Administration of 
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FGF-2 failed to produce any significant protection in the treated groups as compared with 
the control groups (Clark et al., 2000; Bogousslavsky et al., 2002).  Instead, there was an 
increased mortality rate in the treated patients (Clark et al., 2000; Bogousslavsky et al., 
2002).  One hypothesis was that although FGF-2 is a cationic peptide that can be 
transported across the blood brain barrier at a higher rate than most other growth factors 
(Deguchi et al., 2000), due to the limited transportation efficiency, high doses were 
required to produce the central effect, which caused more peripheral side effects, such as 
vasodilatation (Cuevas et al., 1991; Rosenblatt et al., 1994).  In light of our finding of 
FGF-2 induced increased system xC- function, enhanced excitotoxicity must also be 
considered as a possibility.   
 
FGF2 in major depression/anxiety 
FGF-2 was recently suggested as a potential antidepressant (Turner et al., 2008c; 
Perez et al., 2009).  Human postmortem studies indicate decreased FGF system function 
in the frontal cortex (Evans et al., 2004) and hippocampus (Gaughran et al., 2006) of 
patients who suffered from major depression.  Patients with a history of antidepressant 
treatment showed attenuated FGF signaling dysregulation (Evans et al., 2004).  In rodent 
studies, both FGF-2 and FGFR1 levels were decreased in hippocampus following social 
defeat (Turner et al., 2008a).  Also, in a rodent model where rats were selectively bred to 
enhance different emotional behavior, lowered FGF-2 levels in the hippocampus were 
observed in the high anxiety group comparing to the low anxiety group (Perez et al., 
2009).  Exposure to an enriched environment effectively reduced anxiety behavior of the 
high anxiety group, and this was accompanied by increased FGF-2 levels in the 
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hippocampus (Perez et al., 2009).  Chronic exogenous FGF-2 treatment produced the 
same behavioral effects (Perez et al., 2009).  Furthermore, administration of FGF-2 
during development prevented the low responders from exhibiting high anxiety-like 
behavior in adult (Turner et al., 2011).  Administration of FGF-2 was also reported to 
reduce anxiety-like behaviors in the forced swim test model (Turner et al., 2008c).  
Antidepressants were shown to be able to increase FGF-2 levels in brain regions, such as 
prefrontal cortex, hippocampus, and striatum in rodents (Mallei et al., 2002; Maragnoli et 
al., 2004).  Therefore, the evidence of FGF-2 dysregulation in depression is strong.   
 
FGF-2 and schizophrenia 
Schizophrenia is believed to be a result of interplay of both genetic predisposition 
and environmental risk factors (Tsuang, 2000).  Prenatal stress has been suggested as an 
important environmental risk factor (Tsuang, 2000; Terwisscha van Scheltinga et al., 
2010), and it has been shown to decrease FGF2 expression in rat entorhinal cortex and 
striatum, as well as FGF-2 levels in response to acute and chronic stresses in various 
brain regions in adult (Fumagalli et al., 2005).  Social defeat is another risk factor for 
schizophrenia (Selten and Cantor-Graae, 2005; 2007).  In adult rats, both FGF-2 and 
FGFR1 mRNA in hippocampus are downregulated after social defeat (Turner et al., 
2008a).  Smoking of cannabis is another environmental factor that is known to increase 
the risk of developing schizophrenia (Moore et al., 2007).  Cannabinoid receptor type 1 
antagonists have been shown to inhibit axonal growth responses stimulated by FGF-2 
(Williams et al., 2003).  Decreased FGFR1 mRNA levels in dentate gyrus were reported 
in a mouse knockout model of neuronal PAS domain protein 3, a familial mutation 
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involved in schizophrenia (Kamnasaran et al., 2003; Pieper et al., 2005), and two 
different FGFR1 knockout mice showed “schizophrenia-like characteristics” (Ohkubo et 
al., 2004; Shin et al., 2004; Klejbor et al., 2006).   
Schizophrenia is also believed to involve impairments in connections between 
neurons, and between different brain regions, which could result from abnormal 
development (Foucher and Luck, 2006).  FGF-2 has been shown to promote dendritic 
growth in the hippocampus (Rai et al., 2007), as well as promote embryogenesis and 
increase cerebral cortex volume (Vaccarino et al., 1999).  FGF-2 knockout mice show 
decreased neuronal number in the cerebral cortex (Turner et al., 2006).   
Several antipsychotic drugs have been shown to change FGF-2 mRNA levels in 
both human (Hashimoto et al., 2003) and rat hippocampus (Gómez-Pinilla et al., 2000; 
Ovalle et al., 2001; Fumagalli et al., 2004; Maragnoli et al., 2004).  On the other hand, 
postmortem studies showed that FGF-2 mRNA in the hippocampus was decreased in 
clozapine treated schizophrenic patients compared with the nontreated (Gaughran et al., 
2006).   
Therefore, there is a strong association between FGF-2 dysregulation and 
schizophrenia.  Schizophrenia is also associated with decreased glutathione and 
glutamate dysfunction in the brain (Pérez-Neri et al., 2006; Ballatori et al., 2009).  These 
suggest the possibility of FGF-2 dysregulation mediated effects being due to its 
regulation of system xC-.   
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FGF-2 and addiction 
FGF-2 has also been suggested to be involved in addiction.  Agonists of 
dopaminergic D2 receptors increase FGF-2 gene expression in rat prefrontal cortex and 
hippocampus (Fumagalli et al., 2003).  Both acute and chronic exposure to cocaine 
increases FGF-2 expression in rat striatum, prefrontal cortex, hippocampus, and frontal 
cortex (Fumagalli et al., 2006).  Rats that were selectively bred for enhanced drug 
seeking behavior have higher FGF-2 expression levels (Turner et al., 2009).  Postnatal 
administration of FGF-2 enhances acquisition of cocaine self-administration in adults 
(Turner et al., 2009).  However, the functional involvement of FGF-2 in addiction has 
been little studied.   
 
SYSTEM XC- CONTRIBUTION TO CELL DEATH/SURVIVAL 
Oxidative glutamate toxicity 
 In vitro experiments demonstrated that immature neurons rely heavily on system 
xC- activity to take up cystine (Murphy et al., 1990).  They lack glutamatergic receptors; 
so instead of causing excitotoxicity, high levels of extracellular glutamate cause toxicity 
in these cells by competitively inhibiting system xC-, causing oxidative glutamate toxicity 
(Murphy and Baraban, 1990; Schubert and Piasecki, 2001; Lewerenz et al., 2006). The 
oxidative glutamate toxicity is characterized by depletion of GSH (Miyamoto et al., 1989; 
Murphy et al., 1989; Murphy and Baraban, 1990; Murphy et al., 1990), and has 
characteristics of both apoptosis and necrosis (Tan et al., 1998).  Similar oxidative 
glutamate toxicity is also observed in neuroblastoma-primary retina hybrid cells (N18-
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RE105) (Miyamoto et al., 1989), primary rat hippocampal neurons (Murphy et al., 1989), 
a mouse hippocampal cell line (HT-22) (Tan et al., 2001), and primary oligodendrocytes 
(Oka et al., 1993).   
 
Increased system xC- activity: protection against oxidative stress 
 Upregulation of system xC- has been shown to be protective against oxidative 
stress in multiple systems.  Fast proliferating primary brain glial-derived tumor cells 
produce high levels of ROS.  These cells rely primarily on system xC- to take up cystine 
to produce GSH, therefore, inhibiting system xC- decreases the growth of these tumor 
cells (Chung et al., 2005).  High system xC- activity might contribute to the high tolerance 
of human ovarian cancer cells to anticancer treatments (Okuno et al., 2003).  In mouse 
neural stem cells, hypoxic preconditioning increases system xC- function and strengthens 
the cell’s resistance to oxidative glutamate toxicity (Sims et al., 2012).  This 
preconditioning produced protection is absent when either system xC- is blocked by S-4-
carboxyphenyl glycine (CPG), or GSH synthesis is blocked by buthionine sulphoximine 
(Sims et al., 2012).  IGF-1 and TGF-β increase cystine uptake through system xC- on 
dental pulp cells, which leads to protection against oxidative stress (Pauly et al., 2011).  
Retinoic acid increases SH-SY5Y cell (a human dopaminergic neuroblastoma cell line) 
tolerance for 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium ion 
(MPP+) compared to untreated cells (Crockett et al., 2011).  This is because retinoic acid 
increases system xC- activity, which increases GSH levels and protects the cells from 
these oxidative insults (Crockett et al., 2011).  Upregulating Nrf2, one of the well-
characterized pathways that regulate xCT expression, is also known to protect both glial 
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cells and neurons from oxidative stress insults in a PI3K/Akt dependent manner (Shih et 
al., 2003; Wang et al., 2009).  Ceftriaxone protects fibroblasts and the hippocampal cell 
line HT22 from oxidative glutamate toxicity by upregulating system xC- through the 
Nrf2-ARE pathway (Lewerenz et al., 2009).  All of this data suggests that increasing 
system xC- can increase cystine uptake, which can lead to increased glutathione 
production, and provide protection against oxidative stress.   
 
Increased system xC- activity: enhanced excitotoxicity 
 Increasing system xC- activity is not always protective.  Activated microglia have 
increased glutamate release via system xC-, which causes oligodendrocyte excitotoxicity 
through AMPA receptors (Domercq et al., 2007).  Interleukin 1β (IL-1β) upregulates 
system xC- activity selectively on astrocytes, but not neurons (Jackman et al., 2010).  This 
increased system xC- activity is responsible for exacerbating neuronal cell death mediated 
by excitotoxicity when the cultures are exposed to hypoxia (Fogal et al., 2007) or glucose 
deprivation (Jackman et al., 2012).  These studies demonstrate that when system xC- 
activity is increased, glutamate release is also increased, which can potentially exacerbate 
excitotoxicity.   
 
POTENTIAL ROLE OF SYSTEM XC- IN NEUROLOGICAL DISORDERS 
Alzheimer’s disease (AD) 
 AD is a common neurodegenerative disorder in elderly people.  It is characterized 
by progressive memory loss and impaired cognitive function.  Amyloid-β (Aβ) plaques 
and formation of neurofibrillary tangles are the characteristic hallmarks of this disease.  
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Aβ is a normal product of the brain, therefore, the abnormal deposition must be due to an 
over production and/or impaired clearance.  Astrocytes can degrade Aβ (Koistinaho et al., 
2004; Pihlaja et al., 2011).  However, Aβ can make astrocytes reactive, which can 
contribute to neuronal degeneration (Olabarria et al., 2010).  There are increased levels of 
phosphorylated eIF2α (Chang et al., 2002; Unterberger et al., 2006) and ATF4 
(Lewerenz and Maher, 2009) in AD patient’s brains, which are shown to be involved in 
xCT regulation (Lewerenz and Maher, 2009).  In fact, in PC12 cells, induction of eIF2α 
phosphorylation using the specific eIF2α phosphatase inhibitor, salubrinal, increased 
ATF4 levels, system xC- activity, and resistance to Aβ toxicity (Lewerenz and Maher, 
2009).  Therefore, it is most likely that the increase of eIF2α and ATF4 is an adaptation 
to the increased Aβ accumulation.  However, secreted Aβ precursor protein (APP) can 
activate microglia and stimulate system xC- mediated glutamate release from microglia, 
which leads to decreased synaptic density and neuronal viability (Barger and Basile, 
2001).  Therefore, it is not clear whether upregulation of system xC- during AD is 
beneficial or harmful.  
 
Parkinson’s disease (PD)  
 PD is a common nervous system disorder in the elderly that is characterized by 
degeneration of dopaminergic cells in the substantia nigra, resulting in symptoms such as 
difficulties in initiating and finishing voluntary movements, tremors, stiff movements, 
and eventually leads to muscle atrophy (Obeso et al., 2010).  Extensive postmortem 
studies have reported that increased oxidative stress, decreased GSH, and increased 
oxidative damage to lipids, protein and DNA are observed in PD (Jenner and Olanow, 
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1996; Simonian and Coyle, 1996).  Increased striatal glutamate (Massie et al., 2011) and 
decreased nigral glutathione (Schulz et al., 2000) have both been indicated to contribute 
to dopaminergic cell degeneration.   
 Involvement of system xC- in animal models of PD has been studied.  xCT is 
upregulated in the striatum three weeks after 6-OHDA lesion of the nigrostriatal area 
(Massie et al., 2008).  Also, 24 hour 6-OHDA treatment increases system xC- mediated 
cystine uptake in C6 glioma cells in a dose dependent manner (Massie et al., 2008).  In 
xCT null mice, striatal glutamate levels are significantly lower compared to control 
suggesting that system xC- is responsible for the majority of extracellular glutamate 
(Baker et al., 2002; De Bundel et al., 2011; Massie et al., 2011).  The absence of xCT 
decreased the susceptibility of substantia nigra dopaminergic neurons to 6-OHDA 
toxicity (Massie et al., 2011).  These data suggest that system xC- function may have a net 
damaging effect in PD, but it must be kept in mind that the 6-OHDA lesion model is not 
an ideal model of PD.   
 
Amyotrophic lateral sclerosis–Parkinsonism dementia complex (ALS-PDC) 
ALS-PDC is a neurological disease that is also known as lytico-bodig to the 
Chamorro people on the island of Guam (Reed and Brody, 1975).  The disease has 
aspects of ALS, PD, and AD: muscular weakness, spasticity, flaccid paralysis and 
atrophy, and spinal-cord pathology similar to that are seen in ALS, tremors seen in PD, 
neurofibrillary tangles similar to these occurring in brain tissue in AD, and dementia that 
is seen both in PD and AD (Spencer et al., 1987; Liu et al., 2009).  The disease has been 
known to be occurring on Guam for about 200 years (Kurland and Mulder, 1954).  
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However, an outbreak of ALS-PDC in the 1940s to 1960s gained attention because the 
incidence in the Chamorro population was 100 times higher than ALS elsewhere 
(Kurland and Mulder, 1954; Spencer et al., 1986).  The etiology of ALS-PDC remains 
uncertain, dietetic, environmental and genetic factors have all been considered (Ince and 
Codd, 2005).   
At first, genetic factors were considered as the cause since certain villages and 
families had higher rates of ALS-PDC.  However, no genetic mutation that was found 
that could account for the disease, and later studies indicated that adopting the local life 
style and traditional diet had a significant association with the disease (Garruto et al., 
1981).   
 
β-N-methylamino-L-alanine (BMAA) 
BMAA is a non-protein amino acid that is one of the many potential toxins found 
in cycad plants (Spencer et al., 1987; Cox et al., 2003).  It was proposed as a possible 
environmental trigger for ALS-PDC on Guam (Spencer et al., 1987).  The local 
Chamorro people collect the cycad seeds for food and medicine (Bradley and Mash, 
2009).  The local flying foxes (fruit bats) also feed on cycad seeds and it was found that 
BMAA accumulates at high levels in these bats (Cox and Sacks, 2002; Cox et al., 2003; 
Monson et al., 2003).  Flying fox stew was served as a local courtesy dish until its 
extinction in the 1960s, after which time the incidence of ALS-PDC declined.   
BMAA was found to mimic glutamate and activate glutamatergic receptors when 
bicarbonate is present (Weiss and Choi, 1988; Richter and Mena, 1989) (Fig. 1.13), and 
BMAA was found to cause excitotoxicity when physiological concentration of 
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bicarbonate was present in the media (Weiss and Choi, 1988; Weiss et al., 1989b).  The 
BMAA carbonate competes with glutamate at synapses (Richter and Mena, 1989) and 
was shown to have direct binding to the NMDA receptors (Weiss et al., 1989a).   
 
 
FIGURE 1.13.  Structural similarities between the neurotransmitter L-glutamate 
and the neurotoxic carbonate adduct of BMAA.   
From (Erdner et al., 2008) 
 
 Oral bioavailability conducted in cynomolgous monkeys indicated that 80% of the 
administered BMAA was absorbed into the systemic circulation (Duncan et al., 1992).  
More specifically, BMAA crosses the blood-brain barrier, and is retained at high levels in 
the central nervous system (Kisby et al., 1988; Duncan et al., 1991; Smith et al., 1992).   
 BMAA bicarbonate mimicking glutamate is not the only mechanism of BMAA 
actions, since it also increases calcium levels in dissociated rat brain cells in bicarbonate-
free media (Brownson et al., 2002).  In previous studies, we found that BMAA can cause 
cell death of primary cultured cortical neurons by activating glutamatergic receptors such 
as NMDA and mGluR5 (Lobner et al., 2007).  In this thesis we present evidence that 
BMAA also acts as a substrate for system xC- and by doing so both inhibits cystine 
uptake and stimulates glutamate release (Liu et al., 2009).   
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Heavy metals 
Heavy metal toxicity was another hypothesis for ALS-PDC (Johnson and 
Atchison, 2009).  However, no clear evidence of heavy metal toxicity was discovered.  
Since the outbreak of Minamata disease in Japan in 1956, due to an industrial release of 
methylmercury (MeHg) (Harada, 1995), MeHg has received attention for its neurotoxic 
actions both during development and in adults.   
 MeHg is an environmental neurotoxin that is most often consumed through 
contaminated seafood (Rush et al., 2012a).  It is not directly associated with ALS-PDC, 
but has been implicated in neurodegenerative diseases (Wang et al., 2008).  In vivo 
studies suggest that the major localization of MeHg is in glial cells (Charleston et al., 
1995).  Further studies showed that in glial cells MeHg decreases GSH levels (Aschner et 
al., 1994) and disrupts glutamatergic and GABAergic homeostasis (Schousboe et al., 
1992).  In astrocytes, MeHg exposure activates the Nrf2-ARE pathway to upregulate a 
series of antioxidative proteins and increases GSH levels (Wang et al., 2008; Niciu et al., 
2012).  We have shown that MeHg induces increased system xC- activity in primary 
mixed neuronal and glial cortical culture (Fonnum, 1984; Rush et al., 2012b).  
Interestingly, we also showed that MeHg and BMAA synergistically deplete cellular 
GSH levels and induced toxicity to neuronal cells in primary cultures (Petroff, 2002; 
Schousboe and Waagepetersen, 2007; Rush et al., 2012a).   
 
Ischemia/Stroke 
 Stroke is caused by disturbance in the blood supply to the brain, which leads to 
rapid loss of brain functions and often results in permanent neurological damage (Meister 
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and Anderson, 1983; Dringen et al., 2000; Kalra and Ratan, 2008).  It is one of the 
leading causes for death and disability, especially in the elderly population (Erecińska 
and Silver, 1990; Choi, 1998).  Injury induced increases in IL-1β from microglia may 
exacerbate ischemic injury, because IL-1 receptor type I deficient mice show smaller 
infarcts compared to wild type animals following 90 minute reversible middle cerebral 
artery occlusion (Dingledine et al., 1999; Fogal et al., 2007).  In vitro data shows that IL-
1β selectively upregulates system xC- levels on astrocytes but not neurons, and that 
glutamate released from system xC- enhances hypoxic neuronal death (Jackman et al., 
2010; Niciu et al., 2012).  Therefore, IL-1β mediated ischemic damage may be mediated 
by its upregulation of system xC-.  In contrast, erythropoietin has been shown to be 
protective against ischemic neuronal injury (Noguchi et al., 2007; Niciu et al., 2012).  
Interestingly, erythropoietin increases xCT expression in B104 cells, and this 
upregulation can protect the cells from oxidative glutamate toxicity (Dingledine et al., 
1999; Sims et al., 2010).  Ischemic preconditioning, which protects cells from further 
ischemic stress, has also been shown to upregulate system xC- (Jonas et al., 1994; Sims et 
al., 2012).  It is possible that the net effect of upregulation of system xC- on ischemia 
induced cell death is dependent on the cell type on which it is upregulated.   
 
Glioma 
 Gliomas are a type of tumor that arise from glial cells and are the most common 
type of brain tumor (Sontheimer, 2003; Clem and Barth, 2006).  Glioma cells have 
increased need for GSH because of their fast dividing rate.  When glioma cells 
experience oxidative stress, system xC- is rapidly upregulated to maintain the GSH levels 
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(Schneggenburger et al., 1993; Kim et al., 2001).  Glioma cells release a large amounts of 
glutamate into the extracellular space because of the high system xC- activity (Dingledine 
et al., 1999; Ye and Sontheimer, 1999), but they also lack sodium-dependent glutamate 
transporters that clear glutamate from extracellular space (Dingledine et al., 1999; Ye et 
al., 1999).  The combination of these actions cause excitotoxicity to surrounding neuronal 
cells and promotes glioma growth at the same time (Béhé et al., 1995; Premkumar and 
Auerbach, 1997; Takano et al., 2001).  Therefore, glioma cells utilize system xC- to kill 
surrounding neuronal cells by releasing glutamate to cause excitotoxicity to make room 
for additional growth, and take up sufficient amounts of cystine through system xC- to 
make GSH to reduce oxidative stress (Patneau and Mayer, 1990; Burnashev et al., 1995; 
Sontheimer, 2003; 2008).  The high system xC- activity also makes the tumor cells more 
resistant to drugs (Nowak et al., 1984; Lo et al., 2008).  In mouse models of glioma 
tumors, the increased glutamate release can cause epileptic activity, which is a common 
symptom in the majority of glioma patients (Nowak et al., 1984; Dingledine et al., 1999; 
Buckingham et al., 2011).  Because inhibiting system xC- suppresses glioma growth by 
depleting GSH (Johnson and Ascher, 1987; Schell et al., 1995; Chung and Sontheimer, 
2009; Guan et al., 2009), it has been suggested as a treatment for gliomas (Chung and 
Sontheimer, 2009; Grienberger and Konnerth, 2012).   
 
Addiction 
 According to the American Society of Addiction Medicine, “addiction is a 
primary, chronic disease of brain reward, motivation, memory and related circuitry.”  
Decreased levels of basal extracellular glutamate resulting from disrupted system xC- 
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function following chronic cocaine administration has been implicated in the 
pathophysiology of drug addiction (Conn and Pin, 1997; Baker et al., 2003; Ferraguti and 
Shigemoto, 2006; Kim et al., 2008; Lewerenz et al., 2012).  System xC- provides most of 
the extrasynaptic glutamate in nucleus accumbens, which can activate group II mGluRs 
that are autoreceptors localized on presynaptic terminals (Baker et al., 2002; Niciu et al., 
2012).  Intracellularly, group II mGluRs couple to Gi/o to cause decreased cAMP levels 
and eventually lead to decreased neurotransmitter release from the presynaptic terminal 
(Kilbride et al., 2001; Niciu et al., 2012).  Decreased group II mGluRs function has been 
reported after chronic cocaine administration (Xi et al., 2002; Niciu et al., 2012).  
Interestingly, before reinstatement of cocaine seeking, infusing cystine into the nucleus 
accumbens of chronic cocaine administrated animals not only eliminated the decreased 
extracellular glutamate levels, but also prevented acute cocaine induced increase in 
synaptic glutamate release (Choi, 1987; Baker et al., 2003).  Administration of N-
acetylcysteine, a cysteine pro drug, prevented cocaine induced reinstatement (Bains and 
Shaw, 1997; Choi, 1998; Baker et al., 2003; Moussawi et al., 2009).  A logical 
explanation for these results is that chronic cocaine administration decreases glutamate 
release from system xC-, as well as decreases presynaptic group II mGluRs functions, 
which leads to decreased presynaptic inhibition of neurotransmitter release.  After 
extinction, following acute cocaine administration, increased neurotransmitter release 
elicits reinstatement.  However, when extrasynaptic glutamate levels are restored through 
increasing glutamate release by driving system xC- with cystine, presynaptic inhibition is 
restored, which prevents excessive synaptic glutamate release.   
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 The exact mechanism by which cocaine decreases system xC- activity is unknown.  
However, injections of N-acetylcysteine before each self-administration prevented 
chronic cocaine intake escalation (McDonald et al., 1998; Madayag et al., 2007), as well 
as blunted reinstatement (Pitt et al., 2000; Smith et al., 2000; Madayag et al., 2007; Kau 
et al., 2008).  These studies showed that promotion of system xC- function can prevent 
cocaine induced synaptic plasticity to a certain extent.  The beneficial effect of N-
acetylcysteine does not seem to be limited to preventing the synaptic plasticity caused by 
cocaine administration, but also involves the ability to reverse some plasticity caused by 
cocaine administration.  Infusion of N-acetylcysteine after drug administration also 
restores basal extracellular glutamate levels (Yoshioka et al., 1996; Bannerman et al., 
2007; Moussawi et al., 2009), and blunts reinstatement (Erecińska and Silver, 1990; 
Amen et al., 2011).  Ceftriaxone, which induces xCT expression and increases system xC- 
function (Barbour et al., 1988; Zerangue and Kavanaugh, 1996a; Lewerenz et al., 2009), 
was also shown to be able to restore cocaine administration induced decrease in 
extracellular glutamate back to normal and prevent relapse to cocaine seeking (Ventura 
and Harris, 1999; Knackstedt et al., 2010; Witcher et al., 2010).   
 
GENERAL METHODS 
 In this dissertation all of the studies utilize primary cell cultures.  Following is an 
overview of the essential methods used in the studies, with a brief assessment of the 
advantages and limitations of these procedures.   
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Cortical Culture 
 Cortical cell culture is a well-established system for modelling aspects of in vivo 
systems.   For these studies, the cortex is dissected from mice on gestational day 15.  
Cortexes from the same litter are dissociated, then trypsinized before plating in Eagle’s 
minimum essential media containing 5% heat-inactivated horse serum and 5% fetal 
bovine serum on poly-D-lysine and laminin coated 24 well plates.  Cultures are then 
incubated in a 5% CO2 incubator at 37°C for two weeks before being used for 
experiments.  Every six to eight embryos yield one plate.  In a mature mixed plate the 
neurons (~200,000) extend out axons and dendrites to form complicated networks, below 
the neurons, glial cells (~100,000) form a confluent layer.  Similarly, we can also make 
neuronal-enriched and glia-enriched cultures.  By adding cytosine arabinocide, a mitotic 
inhibitor, 2-3 days after plating, glial replication is eliminated producing neuronal-
enriched cultures.  By delaying the dissection until postnatal day one, neurons do not 
survive producing glia-enriched cultures.  These procedures provide a complex, but 
easily reproducible, in vitro system in which to perform studies.   
 However, there are some limitations of this culture system.  The cells can only be 
maintained in vitro for a maximum of about 3 weeks, and even during that time cells are 
continually dying, this limits the ability to mimic low-dose, long-term insults.  Most of 
our experiments are performed on cultures DIV 13-15, with insults lasting 24-48 hours.  
Also, as a common limitation of all cell culture studies, the cells are maintained in a 
media that is optimized for cell health, and is not exactly the same as that in vivo.  These 
limitations should always be kept in mind when interpreting cell culture studies.   
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Cell death assay 
 To quantify the cell death/survival, plate reader based assays are used.  Lactate 
dehydrogenase (LDH) is a large cytosolic enzyme that is normally retained in the cells.  
However, in the event of cell damage/death, the cell membrane is compromised and the 
cellular contents, including LDH, leak out into the extracellular culture media.  The 
amount of LDH being released is proportional to the amount of dead cells.  The assay for 
LDH involves the fact that it catalyzes the conversion of pyruvate to lactic acid using 
NADH.  By sampling the extracellular media, then adding pyruvate and NADH, the 
amount of LDH present can be determined by measuring the rate of NADH loss using an 
absorbance based plate reader.  By comparing experimental groups to the control group 
and full kill (neuronal full kill is achieved by adding 500 µΜ NMDA to induce 
excitotoxicity; glial full kill is achieved by adding 20 µM A23187, a calcium ionophore, 
to cause calcium overload to induce cell death), the relative percentage of cell death can 
be obtained.  Another assay we use to measure neuronal injury is the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay.  MTT can be 
reduced by mitochondrial reductase enzymes forming a dark purple formazan compound.  
By measuring the formazan levels, an indirect measure of cell viability is obtained.  The 
results of these automated assays are confirmed for key experiments by trypan blue 
staining, which is a blue dye that only stains the cells whose membrane is compromised.   
 The automated assays provide a fast and accurate way of assessing cell death.  
However, one should keep in mind that reagents that can potentially alter the function of 
the enzymes that are used for the assays may alter the results.  For example, LDH 
function can be altered by hypoxia (Soñanez-Organis et al., 2012), anoxia (Xiong and 
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Storey, 2012), and growth factors (Matrisian et al., 1985).  Also, these assays utilize 
changes in absorbance to detect color changes to measure enzyme activity.  Therefore, 
reagents that interfere with absorbance detection may dramatically change the results.  
Because of these confounding factors visual examination and estimation of cell death is 
always performed. 
 
14C-cystine uptake 
 Under physiological conditions, system xC- transports cystine into cells in 
exchange for glutamate being transported out.  To assess system xC- activity, we take 
advantage of the amino acid transport function of system xC- and measure the uptake of 
14C-cystine.  The advantage of measuring cystine uptake, as opposed to glutamate uptake 
or release, is that, in our primary cortical cultures, cystine does not directly interact with 
receptors on the cell membrane.  In contrast, there are a large amount of glutamatergic 
receptors and transporters present on the membrane.  However, there are some drawbacks 
to using 14C-cystine uptake as measure of system xc- function.  Cystine taken up by cells 
is quickly broken down into cysteine, and this can happen extracellularly as well.  
Therefore, the uptake data may be a mixture of cystine/cysteine uptake.  Since system xC- 
only transports cystine, not cysteine, this problem can be addressed by blocking system 
xC- to dissect out the system xC- mediated uptake activity.  Intracellularly, cysteine can be 
used to synthesize glutathione, and other cysteine containing molecules, which can be 
exported.  Therefore, with long-term treatment times the uptake data may be a 
compromised by changes in the efflux rate.  To address this concern we compared 14C-
cystine uptake for 2 and 20 minutes with or without 24 hour FGF-2 treatment (Fig. 1.14).  
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The two time points gave similar results, suggesting that 20 minutes is not too long of a 
period to measure uptake under these conditions.  
 
 
FIGURE 1.14.  24 hour FGF-2 treatment on 2 min and 20 min cystine uptake 
Following 24 hour exposure to FGF-2 (100 ng/ml), 14C-cystine uptake was measured for 
2 min and 20 min in astrocyte-enriched cultures.  Data are expressed as 14C-cystine 
uptake in CPM per microgram protein normalized to control (mean±s.e.m., n=4) (A).  * 
indicates significantly different from control uptake.   
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CHAPTER II 
 
 
 
 
β-N-methylamino-L-alanine induces oxidative stress and glutamate 
release through action on system xC−  
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ABSTRACT 
β-N-methylamino-L-alanine (BMAA) is a non-protein amino acid implicated in 
the neurodegenerative disease amyotrophic lateral sclerosis and Parkinson-dementia 
complex (ALS-PDC) on Guam.  BMAA has recently been discovered in the brains of 
Alzheimer’s and ALS patients in North America and is produced by various species of 
cyanobacteria around the world.  These findings suggest the possibility that BMAA may 
be of concern not only for specific groups of Pacific Islanders, but for a much larger 
population.  Previous studies have indicated that BMAA can act as an excitotoxin by 
acting on the NMDA receptor.  We have shown that the mechanism of neurotoxicity is 
actually three-fold; it involves not only direct action on the NMDA receptor, but also 
activation of metabotropic glutamate receptor 5 (mGluR5) and induction of oxidative 
stress.  We now explore the mechanism by which BMAA activates the mGluR5 receptor 
and induces oxidative stress.  We found that BMAA inhibits the cystine/glutamate 
antiporter (system xC-) mediated cystine uptake, which in turn leads to glutathione 
depletion and increased oxidative stress.  BMAA also appears to drive glutamate release 
via system xC- and this glutamate induces toxicity through activation of the mGluR5 
receptor. Therefore, the oxidative stress and mGluR5 activation induced by BMAA are 
both mediated through action at system xC-.  The multiple mechanisms of BMAA 
toxicity, particularly the depletion of glutathione and enhanced oxidative stress, may 
account for its ability to induce complex neurodegenerative diseases.   
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INTRODUCTION 
In the 1950s it was observed that a substantial number of Chamorros, the native 
people of Guam, began developing a disease that showed combined symptoms of 
amyotrophic lateral sclerosis and Parkinson’s dementia complex (ALS-PDC).  The idea 
that BMAA may be involved in this disease began in the 1980s when it was found that 
BMAA was present in cycad seeds which were consumed by the Chamorros (Nunn et al., 
1987; Amara, 1992; Kanai and Hediger, 1992; Storck et al., 1992; Rothstein et al., 1994; 
1996; Diamond and Jahr, 1997; Lehre and Danbolt, 1998) and that injection of BMAA 
into monkey brains induced a Parkinson-like disease (Spencer et al., 1987; Sibson et al., 
1998).  Since its initial proposal, the BMAA hypothesis for the development of ALS-
PDC on Guam has been controversial (Rothstein et al., 1996; Asztely et al., 1997; 
Rusakov and Kullmann, 1998; Cox and Sacks, 2002; Papapetropoulos, 2007).  It was 
challenged by findings that the levels of BMAA in cycad seeds are too low to cause 
damage to the brain or the spinal cord, particularly because the Chamorros thoroughly 
wash the cycad seeds, leading to very low levels of BMAA being consumed (Duncan et 
al., 1990; Hardingham et al., 2002; Riccio and Ginty, 2002; Ivanov et al., 2006; Léveillé 
et al., 2008; Xu et al., 2009; Hardingham and Bading, 2010).  The BMAA hypothesis was 
largely abandoned until the last few years.   
A number of recent studies have brought the BMAA hypothesis back into 
prominence.  First, it was shown that BMAA is biomagnified.  BMAA is produced by 
cyanobacteria that live on cycad plants; it accumulates in the cycad seeds, which are 
eaten by fruit bats, which are in turn eaten by the Chamorros (Cox et al., 2003; Lipton 
and Chen, 2004; Xia et al., 2010).  This system provides a new mechanism by which 
56 
BMAA can be accumulated to high levels in humans.  Second, it was shown that BMAA 
could become protein-associated.  This property allows for BMAA to build up in tissue 
and provides a mechanism for slow release (Lipton and Chen, 2004; Murch et al., 2004b; 
Chen and Lipton, 2006; Xia et al., 2010).  This slow release may provide a possible 
explanation for the delayed onset of ALS-PDC following the time of BMAA 
consumption (Ince and Codd, 2005; Niciu et al., 2012).  Third, cyanobacteria present 
throughout the world have been shown to produce BMAA (Futamachi and Pedley, 1976; 
Roitbak and Fanardjian, 1981; Cox et al., 2005; Banack et al., 2007; Esterhuizen and 
Downing, 2008; Johnson et al., 2008; Metcalf et al., 2008).  Also, BMAA was found not 
only in brain samples of ALS-PDC patients from Guam, but also in the brains of ALS 
and Alzheimer’s disease patients from North America, but not in patients who died of 
other causes (Venance et al., 1997; Murch et al., 2004a; Pablo et al., 2009).  These results 
suggest that BMAA may be of concern not only for people on select Pacific islands, but 
for a much larger population.  Fourth, BMAA at lower concentrations than previously 
believed is neurotoxic.  The original studies in cortical cell culture found that very high 
BMAA concentrations (1-3 mM) were required to induce neuronal death (Ross et al., 
1987; Weiss and Choi, 1988; Weiss et al., 1989a; Oikawa et al., 2005).  A more recent 
study found that BMAA concentrations as low as 30 µM can cause selective death of 
motor neurons (Rao et al., 2006; Butt, 2011; Köles et al., 2011) and cholinergic neurons 
(Venance et al., 1997; Agulhon et al., 2008; Liu et al., 2010), and we found that BMAA 
concentrations as low as 10 µM can enhance neuronal death induced by amyloid-β or 1-
methyl-4-phenylpyridinium ion (MPP+) (Seifert and Steinhäuser, 2001; Lobner et al., 
2007).   
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Given the potential relevance of BMAA consumption to neurodegenerative 
diseases it is important to determine the mechanism of BMAA induced neuronal death.  
We have previously shown that BMAA induces neuronal death through three distinct 
mechanisms: activation of the NMDA and mGluR5 receptors, and induction of oxidative 
stress (Lobner et al., 2007; Benarroch, 2009).  Through electrophysiological recording it 
has been shown that BMAA directly acts on NMDA receptors(Ross et al., 1987; Weiss 
and Choi, 1988; Brownson et al., 2002; Lobner et al., 2007; Poskanzer and Yuste, 2011).  
The current studies were designed to determine how BMAA activates mGluR5 receptors 
and induces oxidative stress.  Evidence is presented that the cystine/glutamate antiporter 
(system xC-) plays an important role in these effects.  System xC- involves the transport of 
cystine into the cell in exchange for glutamate being transported out of the cell.  Given 
the functions of system xC- it seems likely that it plays an important role in neuronal 
survival and death.  By releasing glutamate it can increase extracellular glutamate levels 
and potentially cause excitotoxicity.  Through providing cystine uptake, it can regulate 
cellular glutathione levels and in this way determine whether oxidative stress induced 
neuronal death will occur.  We find that the effects of BMAA on neuronal death involve 
actions on system xC- to both inhibit cystine uptake and increase glutamate release.   
 
MATERIALS AND METHODS 
Materials 
Timed pregnant Swiss Webster mice were obtained from Charles River 
Laboratories (Wilmington, DE). 35S-cystine was from Perkin Elmer Life and Analytical 
Sciences (Boston, MA). 5-(and -6)-carboxy-2′7′-dichlorodihydrofluorescein diacetate 
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(carboxy-H2DCFDA) was from Molecular Probes (Eugene, OR).   
 
Cortical cell cultures 
 Mixed cortical cell cultures containing neuronal cells were prepared from fetal 
(15-16 day gestation) mice as previously described (Cornell-Bell et al., 1990; Lobner, 
2000).  Dissociated cortical cells were plated on 24 well plates coated with poly-D-lysine 
and laminin in Eagles’s Minimal Essential Medium (MEM, Earle’s salts, supplied 
glutamine-free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine 
serum, 2 mM glutamine and glucose (total 21 mM).  Cultures were maintained in 
humidified 5% CO2 incubators at 37°C.  Mice were handled in accordance with a 
protocol approved by our Institutional Animal Care Committee.   
 
Induction of neuronal death 
 All experiments were performed on mixed cultures 13-15 days in vitro (DIV).  
Toxicity was induced by exposure to the toxic agents for 24 hours in media as described 
for plating except without serum.  All exposure media contained 26 mM NaHCO3, as it 
has been shown previously that HCO3- is required for expression of NMDA receptor 
mediated BMAA toxicity (Weiss and Choi, 1988; Fellin et al., 2006; Butt, 2011; Parpura 
et al., 2012).   
 
Assay of neuronal death (LDH release) 
 Cell death was assessed in mixed cultures by the measurement of lactate 
dehydrogenase (LDH) release from damaged or destroyed cells, in the extracellular fluid 
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24 hours after the beginning of the insult.  Blank LDH levels were subtracted from insult 
LDH values and results normalized to 100% neuronal death caused by 500 µM NMDA.  
Control experiments have shown previously that the efflux of LDH occurring from either 
necrotic or apoptotic cells is proportional to the number of cells damaged or destroyed 
(Koh and Choi, 1987; Bezzi et al., 1998; Lobner, 2000; Bezzi et al., 2004; Kreft et al., 
2004) .  Glial cell death (assessed by trypan blue staining) was not observed in any of the 
current studies.  Therefore results are presented as percent neuronal death.   
 
35S-cystine uptake 
 Uptake of cystine was measured by exposure of cultures to 35S-cystine (2 µCi/ml) 
for 20 min in the presence or absence of 3 mM BMAA and/or 1 mM S-4-carboxyphenyl 
glycine (CPG).  Following the exposure to 35S-cystine, the cultures were washed three 
times and dissolved in 1% SDS (250 µl).  An aliquot (200 µl) was removed and added to 
scintillation fluid for counting.  Values were normalized to control 35S-cystine uptake (20 
min exposure to 35S-cystine without BMAA or CPG).   
 
Glutathione assay 
Total glutathione was assayed using a modification of a previous method (Baker 
et al., 1990; Duan et al., 2003; Lobner et al., 2003).  Briefly, following exposure to 
BMAA for three hours, cells were washed with a HEPES buffered saline solution, 
dissolved in 200 µl of 1% salicylic acid, and centrifuged.  A 25 µl aliquot of the 
supernatant was combined with 150 µl of 0.1 M phosphate/5 mM EDTA buffer, 10 µl of 
20 mM dithiobis-2-nitrobenzoic acid, 100 µl of 5 mM NADPH, and 0.2 U of glutathione 
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reductase.  Total glutathione was determined by kinetic analysis of absorbance changes at 
402 nm for 1.5 min, with concentrations determined by comparison to a standard curve.   
 
Assay of intracellular oxidative stress 
Oxidative stress was assayed by measuring dichlorofluorescein oxidation using a 
fluorescent plate reader following a modification of a previous method (Wang and 
Joseph, 1999; Bridges et al., 2004; Lobner et al., 2007).  Cultures were exposed to 3 mM 
BMAA for 3 hours in the presence of 5- (and -6)-carboxy-2’7’-
dichlorodihydrofluorescein diacetate (carboxy-H2DFDA) (10 µM).  The carboxy-
H2DFDA is de-esterified within cells to form a free acid that can then be oxidized to the 
fluorescent 2’7’-dichlorofluorecein (DCF).  After the exposure to carboxy-H2DCFDA, 
cultures were washed three times with culture media lacking serum.  Fluorescence was 
then measured using a Fluoroskan Ascent fluorescence plate reader (Thermo lab 
systems).  The excitation filter was set at 485 nm and emission filter at 538 nm.  
Background fluorescence (no carboxy-H2DCFDA added) was subtracted and the results 
normalized to control conditions (carboxy-H2DCFDA added, but no BMAA exposure).   
 
Analysis of glutamate release 
 Glutamate release was measured following exposure to 3 mM BMAA or cystine 
for 1 hour.  Experiments were performed in the presence of 10 µM MK-801 to block 
potential injury induced by glutamate release.  Samples of the bathing media from the 
cell cultures were assayed for glutamate by using phenylisothiocyanate (PITC) 
derivatization, HPLC (Agilent 1100) separation using a Hypersil-ODS reverse phase 
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column, and ultraviolet detection at a wavelength of 254 nm (Cohen et al., 1986; Lobner 
and Choi, 1996; Magistretti and Pellerin, 1996; Edvinsson and Krause, 2002).  200 µl of 
the bathing media was derivatized with 100 µl of PITC, methanol, triethylamine (2,7,4) 
and dried under vacuum.  These samples were then reconstituted in solvent consisting of 
0.14 M sodium acetate, 0.05% TEA, 6% acetonitrile and brought to pH 6.4 with glacial 
acetic acid.  The above solvent was used as the mobile phase with the column being 
washed between each sample run in 60% acetonitrile, 40% water.  Media glutamate 
concentrations were calculated by normalizing to glutamate standards.  Glutamate 
measurements were found to be linear over the range 0.1-10 µM.   
 
Statistical analysis 
 Differences between test groups were examined for statistical significance by 
means of one-way ANOVA followed by the Bonferroni t-test, with p<0.05 being 
considered significant.   
 
RESULTS 
BMAA toxicity involves the NMDA receptor, mGluR5 receptor, and oxidative stress 
As has been shown before we found that blockade of NMDA receptors with MK-
801 provided significant protection against high concentration BMAA toxicity (Ross et 
al., 1987; Weiss et al., 1989a; Dringen et al., 1993).  As we have shown previously 
(Magistretti and Pellerin, 1996; Lobner et al., 2007) that the mGluR5 antagonist 6-
methyl-2-[phenylethynel]-pyridine (MPEP), and the free radical scavenger, trolox, were 
not protective by themselves, but provided additional protection against BMAA toxicity 
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beyond that provided by MK-801 (Fig. 2.1.).  Furthermore, the combination of these 
agents provided the greatest protection, suggesting that they were acting through distinct 
mechanisms.  The MPEP and trolox were not protective against BMAA toxicity with the 
MK-801 present likely because of the overwhelming toxic effects of BMAA on NMDA 
receptor in the absence of MK-801 (Lobner et al., 2007).  Activation of AMPA/kainate 
receptors does not appear to be involved as we have shown previously that blocking 
AMPA/kainate receptors with CNQX is not protective even in the presence of MK-801 
(Freeman and Crapo, 1982; Simonian and Coyle, 1996; Lobner et al., 2007).  A high 
concentration of BMAA (3 mM) was used so that complete neuronal death was induced 
and the different mechanisms of toxicity could be studied.   
 
 
FIGURE 2.1.  BMAA induced toxicity occurs through multiple mechanisms. 
MK: 10 µM MK-801; MPEP: 50 µM 6-methyl-2-[phenylethynyl]-pyridine (MPEP); trolox: 
100 µM trolox.  Bars show % neuronal cell death (mean ± s.e.m., n = 16-20) quantified 
by measuring release of LDH, 24 hours after the beginning of the insult.   
* indicates significant difference. 
 
63 
BMAA induces oxidative stress through inhibition of system xC- mediated cystine 
uptake 
 
One possibility for induction of oxidative stress by BMAA is that it inhibits 
cystine uptake.  Cystine is the precursor for production of the endogenous free radical 
scavenger, glutathione.  We found that BMAA did in fact greatly attenuate cystine uptake 
(Fig. 2.2.).  Also, the cystine uptake was largely blocked by the cystine/glutamate 
antiporter (system xC-) inhibitor (s)-4-carboxyphenylglycine (CPG), suggesting that 
themajority of the cystine uptake is system xC- mediated.  BMAA did not cause inhibition 
of uptake in the presence of CPG (Fig. 2.2.).  Therefore, it is likely that BMAA attenuates 
the uptake of cystine by inhibition of system xC-.   
 
 
FIGURE 2.2.   BMAA inhibits system xC- mediated cystine uptake. 
BMAA: 3 mM BMAA; CPG: 1 mM S-4-carboxyphenyl glycine (CPG).  Bars show 35S-
cystine uptake during a 20 minute exposure presented as % control (mean ± s.e.m., n = 
16).  * indicates significant difference from control. 
 
 Since cystine uptake is rate-limiting step for glutathione synthesis, glutathione 
levels in response to BMAA treatment was measured.  After a three hour treatment with 
BMAA, glutathione levels were decreased by about 50% (Fig. 2.3.).  Three hour 
exposure was chosen because at this time point there was no significant neuronal death 
observed (less than 10% by the LDH release assay).   
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Since BMAA causes a decrease in the levels of the endogenous free radical 
scavenger glutathione, the total oxidative stress of the cells should be increased.  We 
measured cellular oxidative stress with the fluorescent dye dichlorofluorescein (DCF).  
Treatment with BMAA for 3 hours caused a significant increase in oxidative stress, 
which was blocked by the free radical scavenger trolox (Fig. 2.4.).   
 
 
FIGURE 2.3.  BMAA decreases cellular glutathione levels. 
BMAA: 3 mM BMAA.  Bars show glutathione levels following three hour BMAA exposure 
presented as % control (mean ± s.e.m, n = 16).  * indicates significant difference from 
control. 
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FIGURE 2.4.  BMAA induces oxidative stress. 
BMAA: 3 mM BMAA; trolox: 100 µM trolox.  5-(and -6)-carboxy-2’7’-
dichlorodihydrofluorescein diacetate (10 µM) was added to the cultures during a three 
hour exposure to BMAA.  Bars show % control fluorescence (mean ± s.e.m., n = 12).  * 
indicates significant difference from control.   
 
 The inhibition by BMAA of system xC- mediated cystine uptake suggests that 
BMAA competes with cystine; if like cystine, it is transported, the high levels of BMAA 
used in these studies should lead to increased glutamate release.  We did in fact find that 
3 mM BMAA increased extracellular glutamate.  A similar increase was also caused by 3 
mM cystine (Fig. 2.5.).   
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FIGURE 2.5.  BMAA and cystine stimulate glutamate release. 
BMAA: 3 mM BMAA; cystine: 3 mM cystine.  Bars show extracellular glutamate levels 
following a 1 hour BMAA or cystine exposure (mean ± s.e.m., n = 8).  * indicates 
significant difference from control.   
 
Since BMAA appears to induce glutamate release via system xC-, it is possible 
that this glutamate is responsible for at least part of the glutamate receptor mediated 
neuronal death.  Because BMAA is also a direct agonist for glutamate receptors (Lobner 
et al., 2007; Cucchiaroni et al., 2010), and 3 mM cystine caused a similar increase in 
extracellular glutamate compared with 3 mM BMAA, we used 3 mM cystine to study the 
effect of glutamate released by system xC-.  We found that 3 mM cystine did induce 
neuronal death (Fig. 2.6.).  However, the death was less than that caused by 3 mM 
BMAA, likely due to the fact that cystine is not a direct NMDA receptor agonist like 
BMAA.  However, the cystine toxicity was partially blocked by either MPEP or MK-801.  
No protection was afforded by trolox, as would be expected since a high concentration of 
cystine should not induce oxidative stress.   
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FIGURE 2.6.  Cystine-induced neuronal death is attenuated by MK-801 and MPEP. 
MK: 10 µM MK-801; MPEP: 50 µM MPEP; trolox: 100 µM trolox.  Bars show % neuronal 
cell death (mean ± s.e.m, n = 24) quantified by measuring release of LDH, 24 hours after 
the beginning of the insult.   * indicates significant difference from control (cystine alone).   
 
DISCUSSION 
 We found that BMAA inhibits system xC- mediated cystine uptake leading to 
decreased cellular glutathione.  The process of glutathione production in neurons involves 
a complex series of steps in which cystine is taken up primarily into astrocytes (Freeman 
and Crapo, 1982; Sagara et al., 1993).  The glutathione produced by astrocytes is released 
and converted extracellularly into cysteine, which is taken up by neurons and used by 
them to produce glutathione (Fridovich, 1975; Wang and Cynader, 2000).  Whether the 
action of BMAA to inhibit cystine uptake was primarily on neurons or astrocytes was not 
determined in this study.  Therefore, it is not known if BMAA is initially acting to inhibit 
cystine uptake into neurons, or if it inhibits the uptake of cystine into astrocytes and 
prevents their release of glutathione and therefore restricts the supply of cysteine to 
neurons.  Complicating this simple analysis of BMAA effects of glutathione levels is the 
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finding that blocking system xc- with CPG for as long as 24 hours does not cause a 
decrease in cellular glutathione levels (data not shown).  The fact that BMAA does cause 
a decrease in cellular glutathione indicates that it has actions beyond its effect on system 
xc- mediated cystine uptake.  Other known actions of BMAA that may play a role in its 
effect on glutathione levels include inhibition of the enzymes involved in glutathione 
synthesis (Esterhuizen-Londt et al., 2011), activation of NMDA and mGluR5 receptors 
(Lobner et al., 2007), and results presented in the current study indicating that it can 
cause glutamate release.   
The data presented here strongly suggests that BMAA not only inhibits cystine 
uptake, but also drives system xC- to release glutamate and that this glutamate induces 
neuronal death by acting on mGluR5 receptors and NMDA receptors.  The evidence for 
this is that BMAA and cystine at the same concentration (3 mM) increase extracellular 
glutamate and they both induce NMDA receptor and mGluR5 mediated neuronal death.  
There is no evidence that either of these compounds directly activates mGluR5.  
Unfortunately, CPG could not be used to block the glutamate release because while it is a 
fairly poor substrate for system xC- (Patel et al., 2004; Rush et al., 2012b), at the high 
concentrations needed to compete with the high concentrations of BMAA and cystine 
used in these studies it stimulated glutamate release by itself (data not shown).  Why in 
our studies there was some protection against cystine induced toxicity by MK-801 is not 
clear.  There is no published data indicating that cystine is a direct NMDA receptor 
agonist.  However, we can not exclude the possibly that some of the cystine may be 
converted into cysteine, which is an NMDA receptor agonist (Pullan et al., 1987; 
Ballatori et al., 2009).  Alternatively, the glutamate release stimulated by cystine via 
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system xC- may act to stimulate NMDA receptors.  Furthermore, it has been shown 
activation of mGluR5 and NMDA receptor positively enhances each other’s activity 
(Alagarsamy et al., 1999; Benquet et al., 2002; Chen et al., 2011), which could 
potentially add to the BMAA toxicity.   
 Both oxidative stress and excitotoxicity have been suggested to be regulated by 
system xC- in various cell types.  It has been known for many years that inhibition of 
cystine uptake mediated by system xC- can induce neuronal death by decreasing 
glutathione levels (Murphy et al., 1989; Murphy and Baraban, 1990; Dringen et al., 2000)  
In contrast, astrocytes activated by IL-beta were shown to kill cortical neurons by release 
glutamate via system xC- (Bolaños et al., 1995; Rice and Russo-Menna, 1998; Fogal et 
al., 2007).  Also, microglia can release glutamate via system xC- that can kill cerebellar 
granule cells (Deneke and Fanburg, 1989; Piani and Fontana, 1994), oligodendrocytes 
(Rahman et al., 2005; Domercq et al., 2007), and enhance amyloid-β induced neuronal 
death in cortical cultures (Beutler, 1989; Deneke and Fanburg, 1989; Qin et al., 2006a).  
Finally, glutamate release from kidney dendritic cells via system xC- can inhibit T cell 
activation through actions on mGluR5 receptors (McBean, 2002; Pacheco et al., 2006).  
In the current study we find evidence that oxidative stress induced by the inhibition of 
cystine uptake and excitotoxicity induced by system xC- mediated glutamate release both 
play a role in BMAA induced neuronal death.   
Interestingly, another amino acid implicated in neurological diseases, β-N-oxalyl-
L-α,β-diaminopropionic acid (ODAP), also shares some properties with BMAA: it 
directly activates glutamatergic receptors and is transported by system xC- (Kranich et al., 
1996; Chase et al., 2007).  It is likely that ODAP acts similar to BMAA and causes 
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cytotoxicity through at least some of the same mechanisms.   
 The finding that BMAA not only inhibited cystine uptake by system xC-, but also 
stimulated glutamate release, suggests that it was transported by system xC-.  This 
transport provides a mechanism by which BMAA can accumulate in cells.  There is 
evidence that BMAA may be incorporated into proteins (Murch et al., 2004b; Lobner, 
2009) and could therefore potentially play a role in the protein misfolding found in 
neurodegenerative diseases (McBean, 2002; Uversky, 2008).  Whether BMAA can be 
incorporated into GSH is unknown.  If BMAA does become incorporated into GSH this 
would provide another potential mechanism for its ability to cause depletion of GSH and 
oxidative stress.   
 The importance of BMAA acting on system xC- to induce oxidative stress and 
excitotoxicity at the same time is that this may be partially account for the different types 
of neurological diseases that have been associated with BMAA consumption.  It is 
possible that the different actions of BMAA, in association with varying underlining 
conditions, may lead to the multiple disorders.  Most neurodegenerative diseases appear 
to involve NMDA receptor mediated excitotoxicity (Arrick et al., 1985; Lipton and Chen, 
2004) and oxidative stress (Dringen et al., 1999; Cui et al., 2004), and mGluR5 receptor 
activation has been implicated in Parkinson’s disease as well (Zerangue and Kavanaugh, 
1996b; Chen and Swanson, 2003; Marino et al., 2003; Aoyama et al., 2006).  All of these 
mechanisms of neuronal injury may be enhanced by BMAA.  The finding that BMAA 
causes a depletion of cellular glutathione is of particular importance.  There is evidence 
that glutathione depletion plays a role in Alzheimer’s disease, Parkinson’s disease, and 
ALS (Bannai and Kitamura, 1980; Bains and Shaw, 1997; Liu et al., 2004; Zeevalk et al., 
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2008).  This type of low level, long-term, depletion of glutathione that may be caused by 
the inhibition of cystine uptake could cause the long-term oxidative stress that may 
underlie aspects of neurodegenerative diseases.   
From these results and previous studies, it is obvious that system xC- plays an 
important role in neuronal fate.  We next want to examine if system xC- can be regulated 
by neurotrophic factors, which are naturally occurring molecules, which also regulate 
neuronal fate in multiple ways.  Neurotrophic factors have wide ranging effects in the 
central nervous system, including altering excitotoxicity (Koh et al., 1995; Sato et al., 
1999), oxidative stress (Zhang et al., 1993).    
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CHAPTER III 
 
 
 
 
FUNCTIONAL UPREGULATION OF SYSTEM XC- BY 
FIBROBLAST GROWTH FACTOR-2 
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ABSTRACT 
The cystine/glutamate antiporter (system xC-) is a sodium-independent amino acid 
transport system.  Disruption of this system may lead to multiple effects in the central 
nervous system including decreased cellular glutathione.  Since multiple neurological 
diseases involve glutathione depletion, and disruption of growth factor signaling has also 
been implicated in these diseases, it is possible that some growth factors effects are 
mediated by regulation of system xC-.  We tested the growth factors fibroblast growth 
factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1), neuregulin-1 (NRG), 
neurotrophin-4 (NT-4), and brain derived neurotrophic factor (BDNF) on system xC- 
mediated 14C-cystine uptake in mixed neuronal and glial cortical cultures.  Only FGF-2 
significantly increased cystine uptake.  The effect was observed in astrocyte-enriched 
cultures, but not in cultures of neurons or microglia.  The increase was blocked by the 
system xC- inhibitor (s)-4-carboxyphenylglycine (CPG), required at least 12 hour FGF-2 
treatment, and was prevented by the protein synthesis inhibitor cycloheximide.  Kinetic 
analysis indicated FGF-2 treatment increased the Vmax for cystine uptake while the Km 
remained the same.  Quantitative PCR showed an increase in mRNA for xCT, the 
functional subunit of system xC-, beginning at 3 hours of FGF-2 treatment, with a 
dramatic increase after 12 hours.  Blocking FGFR1 with PD 166866 blocked the FGF-2 
effect.  Treatment with both a PI3-kinase inhibitor (LY-294002) or a MEK/ERK inhibitor 
(U0126) for 1 hour prior to and during the FGF-2 treatment blocked the increased cystine 
uptake.  The upregulation of system xC- by FGF-2 may be responsible for some of the 
known physiological actions of FGF-2.   
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INTRODUCTION 
The function of system xC- makes it likely to play an important role in regulating 
many processes in the central nervous system.  By releasing glutamate, it can increase 
extracellular glutamate levels, which may alter neuronal plasticity and potentially cause 
excitotoxicity; Through providing cystine uptake, it supplies the substrate for cellular 
glutathione synthesis, and in this way may determine whether oxidative stress induced 
neuronal death will occur.   
There is considerable evidence that glutamate released from system xC- is 
involved in both physiological and pathological processes.  Physiologically glutamate 
release from system xC- plays a role at the photoreceptor synapse (Hu et al., 2008) and in 
regulating immune cell function (Xue and Field, 2011).  It is known that glutamate 
release from system xC- can cause toxicity, and this is observed in many pathological 
processes.  Activated astrocytes release glutamate via system xC- that can kill cortical 
neurons (Fogal et al., 2007).  Also activated microglia release glutamate via system xC- 
that can kill cerebellar granule cells (Piani and Fontana, 1994) and enhance amyloid-beta 
induced neuronal death in cortical cultures (Qin et al., 2006b).   
Glutathione is known to detoxify superoxide in a reaction catalyzed by 
glutathione peroxidase forming disulfide/oxidized glutathione.  This reaction is 
accomplished by redox changes at the sulfhydryl group of the cysteine residue of 
glutathione (Dringen and Hirrlinger, 2003).  The cystine uptake mediated by system xC- 
appears to play a critical role in regulating cellular glutathione levels, because de novo 
synthesis of glutathione in the brain is rate-limited by the uptake of cystine (Sagara et al., 
1993).  Specifically, astrocytes express high levels of system xC- and have high levels of 
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cystine uptake (Dringen et al., 2000; Lewerenz et al., 2006), while neurons of the central 
nervous system have limited capacity for cystine uptake, and are reliant primarily on 
astrocytes for the provision of cysteine and cysteinylglycine for neuronal glutathione 
production (Dringen et al., 1999).  The first evidence that system xC- could play a role in 
neuronal death was provided when it was shown that high concentrations of glutamate 
could competitively inhibit cystine uptake leading to an oxidative stress mediated 
neuronal death (Murphy et al., 1990).  This type of toxicity was shown to occur before 
glutamate receptors developed (Murphy and Baraban, 1990) and to involve depletion of 
glutathione (Ratan et al., 1994).  In contrast to the enhancement of neurotoxicity caused 
by releasing glutamate, system xC- activity on non-neuronal cells can be protective to 
neurons by generating and releasing glutathione.  Overexpression of xCT, the functional 
subunit of system xC-, in astrocytes has been shown to enhance glutathione release and 
protect neurons from oxidative stress (Shih et al., 2006).  Since neurological diseases 
including schizophrenia, depression, Alzheimer’s disease, and Parkinson’s disease have 
all been associated with depletion of cellular glutathione (Ballatori et al., 2009; Dean et 
al., 2009; Shibasaki et al., 2009; Maes et al., 2011), it is possible that altered system xC- 
function plays a role in these diseases.   
Neurotrophic factors have wide ranging effects in the central nervous system 
including altering excitotoxicity (Koh et al., 1995; Chintala et al., 2005), oxidative stress 
(Zhang et al., 1993; Shih et al., 2006), and cellular glutathione levels (Pan and Perez-
Polo, 1993; Sato et al., 1999).  The overlapping actions of growth factors and system xC- 
suggest the possibility that some neurotrophic factor effects may be mediated by 
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regulation of system xC-.  Therefore we tested the effects of a number of well-established 
neurotrophic factors on system xC- function.   
 
MATERIALS AND METHODS 
Materials 
Timed pregnant Swiss Webster mice were obtained from Charles River 
Laboratories (Wilmington, DE).  Serum was from Atlanta Biologicals (Lawrenceville, 
GA).  Growth factors were from Alomone Labs (Jerusalem, Israel).  14C-cystine was from 
Perkin Elmer (Waltham, MA).  All other chemicals were obtained from Sigma (St. Louis, 
MO).   
 
Cortical cell cultures 
Mixed cortical cell cultures containing glial and neuronal cells were prepared 
from fetal (15-16 day gestation) mice as previously described (Lobner, 2000; Sasaki et 
al., 2002).  Dissociated cortical cells were plated on 24-well plates coated with poly-D-
lysine and laminin in Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied 
glutamine-free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine 
serum, 2 mM glutamine and glucose (total 21 mM).  Neuron-enriched cultures were 
prepared exactly as above with the addition of 10 µM cytosine arabinoside 48 hours after 
plating to inhibit glial replication.  In these cultures <1% of cells are astrocytes (Dugan et 
al., 1995; Sato et al., 2000; Sasaki et al., 2002; Rush et al., 2010).  Astrocyte-enriched 
cultures were prepared as described for mixed cultures except they are from cortical 
tissue taken from post-natal day 1-3 mice (Choi et al., 1987; Schwartz and Wilson, 1992; 
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Venugopal and Jaiswal, 1996; Rush et al., 2010).  Microglia cultures were prepared by 
first growing astrocyte-enriched cultures, then shaking the microglia free and plating 
them in media containing 10 ng/ml colony stimulating factor (CSF) (Itoh et al., 1999; 
Barger and Basile, 2001).  Cultures were maintained in humidified 5% CO2 incubators at 
37°C.  Mice were handled in accordance with a protocol approved by our institutional 
animal care committee and in compliance with the Public Heath Service Policy on 
Humane Care and Use of Laboratory Animals.  All efforts were made to minimize animal 
suffering and reduce the number of animals used.   
 
14C-cystine uptake 
System xC- mediated uptake of radiolabeled cystine was assayed as previously 
described with modifications (Itoh et al., 1999; Liu et al., 2009).  Growth factors were 
added to the serum containing media for the indicated durations.  Cultures were then 
washed into HEPES buffered saline solution and immediately exposed to 14C-cystine 
(0.025µCi/ml) for 20 min.  Following 14C-cystine exposure, cultures were washed with 
ice cold HEPES buffered saline solution and dissolved in 250 µl sodium dodecyl sulfate 
(0.1%).  An aliquot (200 µl) was removed and added to scintillation fluid for counting.  
In some experiments an aliquot was also used to measure cellular protein levels by the 
BCA assay.  Values were normalized to 14C-cystine uptake in untreated control on the 
same experimental plate.  Kinetic analysis of cystine uptake was performed as previously 
described (Lee and Johnson, 2004; Fogal et al., 2007).  Uptake of 14C-cystine was 
measured over a range of cystine concentrations: 0.1 µM, 0.3 µM, 1µM, 3 µM, 10 µM, 
and 30 µM.  Kinetic analysis was performed using the Hanes-Woolf plot where 
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[substrate]/velocity is plotted against [substrate].  The slope corresponds to 1/Vmax, while 
the X-intercept corresponds to the Km.   
 
Reverse transcription quantitative real-time PCR (RT-qPCR) 
Transcriptional expression of xCT in astrocyte-enriched cultures after stimulation 
with FGF-2 was examined using RT-qPCR.  Briefly, after various durations of treatment 
with FGF-2 cells were washed 3 times with cold PBS.  Total RNA was isolated with 
TRIzol extraction (Invitrogen; Carlsbad, CA) according to manufacturer’s protocol, 
cDNA was synthesized using the Reverse Transcription System (Promega; Madison, WI) 
from 1 µg of total RNA following the manufacturer’s protocol.  All products were 
amplified on a StepOne real-time PCR system (Applied Biosystems; Carlsbad, CA) using 
100 ng of cDNA, PerfeCTa SYBR Green FastMix with ROX (Quanta Biosciences; 
Gaithersberg, MD), and the following primers: gapdh mouse forward-AAG GGC TCA 
TGA CCA CAG TC; gapdh mouse reverse-GGA TAC AGG GAT GAT GTT CT; xCT 
mouse forward-AGG GCA TAC TCC AGA ACA CG; xCT mouse reverse-GAC AGG 
GCT CCA AAA AGT GA.  xCT expression was normalized to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (gapdh).  Quantitative PCR was used to 
determine fold increase of xCT mRNA using the 2-ΔΔCT method.   
 
Statistical analysis 
Differences between test groups were examined for statistical significance by 
means of one-way ANOVA followed by the Bonferroni correction post-hoc test, with 
p<0.05 being considered significant.   
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RESULTS 
The effects of FGF-2, IGF-1, NRG, NT-4, and BDNF, each of which have been 
shown to have actions on cortical cells (Bannai, 1984; Koh et al., 1995; Anton et al., 
1997; Erickson et al., 2002; Sasaki et al., 2002; Lobner et al., 2003), were tested on 14C-
cystine uptake in mixed neuronal and glial cortical cultures.  In these cultures 
approximately 90% of cystine uptake is mediated by system xC- (Lee and Johnson, 2004; 
Liu et al., 2009; Lobner, 2009).  Following 24 hour growth factor treatment, only FGF-2 
caused a significant increase in cystine uptake (Fig. 3.1.).  Importantly, the growth factors 
were added to the cultures on DIV 13-14, a time point at which there was already a 
confluent layer of astrocytes.  None of the growth factors had a significant effect on total 
cellular protein levels (data not shown).   
 
 
FIGURE 3.1.   Growth factor effects on cystine uptake in cortical cultures. 
Treatment for 24 hours with 100 ng/ml of the growth factors on mixed neuronal and glial 
cultures.  FGF-2: fibroblast growth factor-2; IGF-1: insulin-like growth factor-1; NRG: 
neuregulin; NT-4: neurotrophin-4; BDNF: brain derived neurotrophic factor.  Cultures 
were exposed to growth factors for 24 hours, washed into a growth factor free media, 
and 14C-cystine uptake measured for 20 min.  Bars show % control (mean ± s.e.m., n = 
12-16).  * indicates significantly different from control uptake.   
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This effect of FGF-2 on cystine uptake does not appear to be limited to cortical 
astrocytes.  We also examined some growth factors that are known to have effects on 
spinal cord, and found a similar regulatory effect of FGF-2 on cystine uptake in spinal 
cord glial cultures (Fig. 3.2.).   
 
 
FIGURE 3.2.  Growth factor effects on cystine uptake spinal cord glial cultures. 
24 hour treatment with growth factors (100 ng/ml) on primary mouse spinal cord glial 
cultures.  FGF-2: fibroblast growth factor-2; NT-4: neurotrophin-4; IGF-1: insulin-like 
growth factor-1; NRG: neuregulin; BMP-2: Bone morphogenetic protein 2; BDNF: brain 
derived neurotrophic factor. Cultures were exposed to growth factors for 24 hours, 
washed into a growth factor free media, and 14C-cystine uptake measured for 20 min. 
Spinal cord glia cultures were prepared as cortical glial cultures except they were 
prepared from whole spinal cords from postnatal day one mice.  Bars show % control 
(mean±s.e.m., n=12-16). * indicates significantly different from control uptake.  
 
We also examined FGF-2 actions on neuronal-enriched, astrocyte-enriched, and 
microglial cultures to see which cell type mediates the FGF-2 effect.  We found that the 
FGF-2 effect only occurred in astrocyte-enriched cultures (Fig. 3.3.).  We have shown 
previously that the majority of cystine uptake in cortical cultures is into the glial cells 
(Lobner, 2009).  Astrocyte-enriched cultures prepared by the current method are known 
to also contain microglial cells (Shih et al., 2003; Hamby et al., 2006; Wang et al., 2009).  
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However, since there was no effect of FGF-2 in the microglial cultures, we believe that 
the effect occurs on astrocytes.  Therefore, all of the following experiments were 
performed using the astrocyte-enriched cultures.  We next tested whether the effect of 
FGF-2 was on system xC- mediated cystine uptake.  More than 90% of cystine uptake 
was blocked by the system xC- antagonist (s)-4-carboxyphenylglycine (CPG), and the 
increase caused by 24 hour treatment with FGF-2 was completely blocked by CPG (Fig. 
3.4.).   
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FIGURE 3.3.  Effects of FGF-2 on cystine uptake in neuronal-enriched cultures (A), 
astrocyte-enriched cultures (B), and microglial cultures (C).   
Cultures were exposed to FGF-2 (100 ng/ml) for 24 hours, washed into a growth factor 
free media, and 14C-cystine uptake measured for 20 min.  Bar show % control 
(mean±s.e.m., n=8).  * indicates significantly different from control uptake.   
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FIGURE 3.4.   FGF-2 induced increase in cystine uptake is mediated by 
system xC-. 
Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 24 hours, washed 
into a growth factor free media, and 14C-cystine uptake measured for 20 min with or 
without the system xC- antagonist (s)-4-carboxyphenylglycine (200 µM CPG).  Bars show 
% control (mean±s.e.m., n=8).  * indicates significantly different from control uptake.   
 
The previous studies were all performed using a 24 hour growth factor treatment.  
We next performed a time course of FGF-2 treatment.  A significant effect of FGF-2 
treatment was first observed after a 12 hour exposure (Fig. 3.5A.).  None of the growth 
factors tested in Fig. 3.1., including FGF-2, had an effect with acute treatment (20 min 
prior to and during the cystine uptake-data not shown).  Treatment with the protein 
synthesis inhibitor cycloheximide during the 24 hour FGF-2 treatment blocked the FGF-2 
induced increase in cystine uptake (Fig. 3.5B.).   These results suggest an upregulation of 
the number of transporters.   
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FIGURE 3.4.   Time and protein synthesis dependent changes in cystine uptake 
induced by FGF-2 treatment on astrocyte-enriched cultures. 
(A) Cultures were exposed to FGF-2 (100 ng/ml) for the indicated period of time, washed 
into a growth factor free media and 14C-cystine uptake measured for 20 min.  Bars show 
% control (mean±s.e.m., n=32).  (B) Cultures were exposed to FGF-2 (100 ng/ml) for 24 
hours with or without the protein synthesis inhibitor cycloheximide (CHX, 200 ng/ml), 
washed into a growth factor and inhibitor free media, and 14C-cystine uptake measured 
for 20 min.  Bars show % control (mean±s.e.m., n=8).  * indicates significantly different 
from control uptake.   
 
We also assessed the kinetic changes of the transporter.  Treatment with FGF-2 
for 24 hours caused a significant increase in the Vmax of the transporter activity, but no 
change in the Km (Fig.  3.6.).  
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FIGURE  3.6.  Kinetic analysis of FGF-2 effects on cystine uptake. 
Following 24 hour exposure to FGF-2 (100 ng/ml), 14C-cystine uptake was measured for 
20 min in astrocyte-enriched cultures in the presence of varying concentrations of 
cystine.  Data are expressed as 14C-cystine uptake in CPM per microgram protein 
(mean±s.e.m., n=4) (A).  Vmax (1/slope) and Km (-X-intercept) were determined using the 
Hanes-Woolf plot (B).  * indicates significantly different from control uptake.   
 
Finally, a time course of mRNA levels of xCT, the functional subunit of system 
xC-, measured with RT-qPCR, showed an increase starting after 3 hours of FGF-2 
treatment, with a large increase after 12 hours (Fig. 3.7.).   
 
 
FIGURE 3.7.  Time course of changes in xCT mRNA in astrocyte-enriched cultures 
assessed by RT-qPCR following different durations of FGF-2 (100 ng/ml) 
treatment. 
Bars show % control (mean ± s.e.m.), data is from 4 independent experiments run in 
duplicate for n=8.  * indicates significantly different from control. 
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FGF-2 can act on a number of FGF receptors.  FGFR1 is highly expressed in the 
brain (Gonzalez et al., 1995; Wang et al., 2009) and it is found at high levels in astrocytes 
in the current culture system (Lobner and Ali, 2002; Sato et al., 2004; Lewerenz and 
Maher, 2009).  Therefore we tested the effects of an antagonist of this receptor on the 
FGF-2 treatment induced increase in system xC- function.  The FGFR1 antagonist PD 
166866 caused a concentration dependent inhibition of FGF-2 stimulated cystine uptake 
(Fig.  3.8A.).  We next attempted to determine the signaling pathway of the FGF-2 effect.  
We tested the effects of selective inhibitors of the MEK/ERK (U0126) (Favata et al., 
1998; Kilberg et al., 2005) and PI3-kinase (Vlahos et al., 1994) pathways on the FGF-2 
stimulated cystine uptake.  Inhibition of either the MEK/ERK or PI3-kinase pathway 
partially blocked the FGF-2 stimulated cystine uptake, while the combination of the 
inhibitors completely blocked the increase (Fig.  3.8B.).   
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FIGURE 3.8.  FGF-2 stimulation of cystine uptake is mediated by activation of 
FGFR1 and both the MEK/ERK and PI3-kinase pathways. 
(A) Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 24 hours with or 
without the FGFR1 inhibitor (PD 166866), washed into a growth factor and inhibitor free 
media, and 14C-cystine uptake measured for 20 min.  Bars show % control 
(mean±s.e.m., n=12).  (B) Astrocyte-enriched cultures were exposed to FGF-2 (100 
ng/ml) for 24 hours with or without the MEK/ERK inhibitor (10 µM U0126) or the PI3-
kinase inhibitor (45 µM LY-294002) added 1 hour prior to and during the FGF-2 
exposure, washed into a growth factor and inhibitor free media, and 14C-cystine uptake 
measured for 20 min.  Bars show % control (mean ± s.e.m., n = 18).  * indicates 
significantly different from control uptake.  # indicates significantly different from FGF-2 
stimulated uptake. 
 
DISCUSSION 
The upregulation of system xC- induced by the FGF-2 treatment has multiple 
implications for understanding the biological effects of FGF-2 and its potential use as a 
therapeutic agent.  Both dysregulation of FGF-2 signaling and system xC- function have 
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been implicated in psychiatric disorders such as schizophrenia, depression, and addiction.  
As FGF-2 and regulators for system xC- have been suggested for therapeutic use, it is 
important to understand the mechanism of regulation of system xC-.  Also, upregulation 
of system xC- must be taken into account when considering the use of FGF-2 for the 
treatment of neurological conditions, particularly those that involve excitotoxicity.   
The evidence suggesting the involvement of dysregulation of the FGF-2 system in 
schizophrenia is substantial (Terwisscha van Scheltinga et al., 2010).  FGF-2 is involved 
in neurogenesis and normal brain development (Zechel et al., 2010).  FGFR1 is widely 
expressed in the brain (Gonzalez et al., 1995) and is required for proliferation of 
hippocampal stem cells (Ohkubo et al., 2004).  Therefore FGF-2 system signaling 
dysregulation may be involved in altered development in schizophrenia.  Supporting this 
idea, in post-mortem brains from schizophrenia patients there was found to be increased 
FGFR1 expression in the CA4 region of the hippocampus (Gaughran et al., 2006) and 
there is increased expression of FGF-2 in the serum of schizophrenia patients (Hashimoto 
et al., 2003).  It is interesting to note that disruption of MEK/ERK and PI3-kinase 
signaling have also been implicated in developmental diseases, such as schizophrenia 
(Waite and Eickholt, 2010; Yuan et al., 2010).  We found that the action of FGF-2 to 
upregulate system xC- function was partially dependent on both MEK/ERK and PI3-
kinase signaling.  The results presented in the current study of FGF-2 effects on system 
xC- that are mediated by FGFR1 provide a potential mechanism by which defects in FGF-
2 signaling leads to developmental disorders.   
There are decreased levels of glutathione in schizophrenics (Raffa et al., 2011) 
and an animal model of schizophrenia involves the post-natal treatment with buthionine 
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sulfoximine, an inhibitor of a glutathione synthesis (Cabungcal et al., 2007).  In one study 
it was found that in an animal model of schizophrenia there was decreased system xC- 
activity, although in the brain of human schizophrenics there was a slight increase in xCT 
expression (Baker et al., 2008).  Therefore, it is possible that increased FGF-2 signaling is 
a compensatory mechanism in schizophrenia to increase xCT expression to increase 
system xC- activity.  However, a great deal more work determining the time course of 
changes in FGF-2 system signaling, system xC- function, glutathione levels, development 
changes, and development of the disease is necessary.   
Disruption of FGF-2 signaling may also be involved in depression.  In the post-
mortem brains of depressed patients there is reduced mRNA for FGF-2, but increased 
mRNA for FGFR1 (Gaughran et al., 2006).  Treatment with FGF-2 has antidepressant 
effects in mouse models of depression and reversed the decrease in neurogenesis in the 
hippocampus of these mice (Zechel et al., 2010).   
Alterations in both system xC- and FGF-2 have been implicated in cocaine 
addiction.  In adult rats, following withdrawal from repeated cocaine, there is decreased 
function of system xC- in the nucleus accumbens (Baker et al., 2003).  Repeated cocaine 
administration increases FGF-2 mRNA in the striatum and prefrontal cortex (Fumagalli 
et al., 2006), while it decreases FGFR1 mRNA in the hippocampus but increases it in the 
prefrontal cortex (Turner et al., 2008b).  Due to differences in the areas of the brain 
assessed, it is at this time not possible to draw conclusions regarding the interaction 
between system xC- and FGF-2 during addiction.  However, it is clear that both are 
changed.   
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We showed that 24 hour treatment with FGF-2 increases cystine uptake through 
system xC- selectively on primary cortical astrocytes, but not neurons or microglia.  This 
effect does not appear to be limited to cortical astrocytes.  We found a similar regulatory 
effect of FGF-2 on cystine uptake through system xC- in spinal cord glial cultures.  The 
result that FGF-2 also increases cystine uptake in spinal cord gial cultures is especially 
interesting because of a recent study showing that knocking out FGF-2 can delay disease 
progression in the SOD1 ALS mouse model (Thau et al., 2012).  One possible 
explanation for this result is that the lack of FGF-2 signaling leads to decreased system 
xC- activity in the ALS mice, and the protection would then be due to decreased 
glutamate release from system xC- and decreased excitotoxicity.  However, what role 
FGF-2 plays in ALS is unclear.  Post mortem studies revealed that there was no change in 
FGF-2 or FGFR1 mRNA in ALS patients compared to control (Petri et al., 2009).  
Preliminary data from our laboratory on mutant SOD1 mice showed a significant increase 
in system xC- function in spinal cord slices even before the animals showed any 
symptoms (unpublished data).  Future studies on FGF-2 signaling and regulation of 
system xC- in the SOD1 model can potentially help clarify the involvement of FGF-2 and 
system xC- in ALS.   
The function of system xC- makes it likely to play an important role in regulating 
neuronal survival and death; by releasing glutamate it can increase extracellular 
glutamate levels and potentially cause excitotoxicity, through providing cystine to the cell 
it regulates cellular glutathione levels and in this way may protect cells against oxidative 
stress.  Both excitotoxicity and oxidative stress play a role in neurodegenerative diseases 
(ALS) (Bains and Shaw, 1997; Lau and Tymianski, 2010).  The dual nature of system xC- 
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means that it may either protect against or enhance neuronal death depending on the 
relative importance of excitotoxicity and oxidative stress in each disease.   
FGF-2 was tested in clinical trials for the treatment of stroke.  It was found that 
FGF-2 treatment caused roughly a doubling of the mortality rate (Clark et al., 2000; 
Bogousslavsky et al., 2002).  While there are many possible reasons for a lack of 
protective effects of FGF-2, the increase in mortality indicates that, in this situation, it 
was having injury potentiating effects.  Could an increase in system xC- be responsible 
for the increased mortality following FGF-2 treatment?  Certainly excitotoxicity plays a 
role in cerebral ischemia (Choi, 1998) and system xC- activity can enhance excitotoxicity 
(Fogal et al., 2007).  However, FGF-2 has multiple effects on systems that can alter 
neuronal death.  For example, in the central nervous system, it increases AMPA receptor 
expression (Cheng et al., 1995), and decreases NMDA receptor expression (Mattson et 
al., 1993).  Therefore, the net effect of FGF-2 on neuronal death in various conditions 
will depend on many factors.  We began to explore the net effect of FGF-2 by testing 
whether long-term upregulation of system xC- by FGF-2 directly induces neuronal death.    
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CHAPTER IV 
 
 
 
 
FGF-2 INDUCES NEURONAL DEATH  
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ABSTRACT 
FGF-2 upregulates system xC- selectively on astrocytes, which will lead to both 
increased cystine uptake, with increased glutathione production, and increased 
extracellular glutamate.  While the increased intracellular glutathione can contribute to 
decreased oxidative stress, the increased glutamate release can potentially lead to 
excitotoxicity to neurons.  To test this hypothesis, we performed a long-term treatment 
(48 hours) of FGF-2 in mature mixed neuronal and glial cultures.  Treatment with FGF-2 
for 48 hours caused a significant neuronal death in these cultures.  This cell death was not 
observed in neuronal-enriched cultures, or astrocyte-enriched cultures, suggesting the 
toxicity is a result of neuron-glia interaction.  Blocking system xC- eliminated the 
neuronal death.  Since increasing cystine uptake is unlikely to induce toxicity, we 
examined the involvement of glutamate release.  The general AMPA/kainate receptor 
antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) 
abolished the neuronal toxicity induced by FGF-2 treatment, and surprisingly, the NMDA 
receptor antagonist memantine did not.  When cultures were exposed directly to 
glutamate, either NBQX or memantine blocked the neuronal toxicity.  The mechanism of 
this altered profile of glutamate receptor mediated toxicity by FGF-2 is unclear.  The 
selective calcium permeable AMPA receptor antagonist 1-naphthyl acetyl spermine 
(NASPM) failed to offer protection. FGF-2 has been suggested to be able to decrease 
NMDA receptor mediated toxicity by both reducing NMDA receptor expression and 
causing a faster inactivation.  FGF-2 has also been shown to increase GluR1 expression, 
as well as increased calcium influx.  Therefore, the most logical explanation for the 
results is that 48 hour FGF-2 treatment induces AMPA receptor toxicity through 
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increased system xC- function resulting in increased release of glutamate.  At the same 
time, FGF-2 decreases neuronal sensitivity to NMDA receptor mediated toxicity, and 
possibly enhances sensitivity to AMPA receptor mediated toxicity, although we cannot 
exclude the possibility that FGF-2 treatment sensitizes the neurons to normal system xC- 
mediated glutamate release.   
 
INTRODUCTION 
Fibroblast growth factor 2 (FGF-2), despite its discovery in fibroblasts, is widely 
expressed throughout the brain (Eckenstein, 1994; Dono, 2003).  FGF-2 can activate 
members of the FGF receptor family leading to activation of several intracellular 
pathways, including PI3K/Akt and MEK/ERK pathways (Reuss and Bohlen und 
Halbach, 2003).  It has been demonstrated to be involved in development (Ohkubo et al., 
2004), adult neurogenesis (Mudò et al., 2009), and tissue repair (Reuss and Bohlen und 
Halbach, 2003).  Dysregulation of FGF-2 signaling has been implicated in acute and 
chronic neurodegenerative diseases, such as stroke (Alzheimer and Werner, 2002), 
traumatic brain injury (Mellergård et al., 2012), and Alzheimer’s disease (Mark et al., 
1997), as well as psychiatric disorders such as schizophrenia (Terwisscha van Scheltinga 
et al., 2010), stress (Molteni et al., 2001; Frank et al., 2007), addiction (Flores and 
Stewart, 2000), and major depression (Evans et al., 2004).  The use of FGF-2 for 
treatment for stroke in clinical trials has been attempted but without success (Clark et al., 
2000; Bogousslavsky et al., 2002).   
System xC- is a cystine/glutamate antiporter on the cell membrane (Sato et al., 
1995b; Liu et al., 2011).  Physiologically, system xC- takes up cystine and releases 
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glutamate in exchange at a 1:1 ratio (Sato et al., 1999).  The direction of transport is 
determined by the high glutamate levels and low cystine levels intracellularly.  Once 
cystine is taken up it is rapidly reduced to cysteine, which can then be used to synthesize 
protein, or glutathione (GSH), an important endogenous antioxidant in the brain (Meister 
and Anderson, 1983).  GSH and cysteine can both be released into the extracellular 
space, typically by astrocytes, to regulate the redox state of the brain (Wang and Cynader, 
2000; Dringen and Hirrlinger, 2003).  Also, the extracellular cysteine is taken up by 
neurons to synthesize GSH (Wang and Cynader, 2000; Lewerenz et al., 2006; Escartin et 
al., 2011).  The glutamate released by system xC- can have multiple effects.  Glutamate is 
the most important excitatory neurotransmitter in the central nervous system.  Along with 
mediating excitatory neurotransmission at synapses, glutamate released from astrocytes is 
also believed to regulate synaptic activity and plasticity through activating parasynaptic 
and extrasynaptic receptors (Asztely et al., 1997; Hardingham et al., 2002).  However, 
high extracellular glutamate levels can cause neuronal death through excitotoxicity, 
typically resulting from high NMDA receptor activation leading to excess calcium influx 
triggering cell death (Choi et al., 1987).   
System xC- has been shown to be widely expressed, especially in the central 
nervous system (Sato et al., 2002; Burdo et al., 2006).  In vitro cell culture studies have 
shown that immature neuronal cells rely on system xC- to take up cystine (Murphy et al., 
1990).  When immature neuronal cell cultures are incubated with high levels of 
glutamate, glutamate competitively inhibits cystine uptake through system xC- and the 
cells die from oxidative stress (Murphy et al., 1989).  This mechanism of neuronal death 
is called oxidative glutamate toxicity (Schubert and Piasecki, 2001).  This type of 
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glutamate toxicity is distinct from glutamate toxicity in mature neuronal cells, which 
results from over-stimulation of NMDA receptors leading to excessive calcium influx, 
and it is called excitotoxicity (Choi, 1987).  Also, in mature cell cultures, neurons show 
low levels of system xC- activity, while astrocytes exhibit high levels of system xC- 
activity (Lobner, 2009).  This shift of function indicates that as cells mature, they take on 
more specialized tasks and cooperate as a system (Fellin and Carmignoto, 2004; 
Stipursky et al., 2011; Suzuki et al., 2011).   
The dual actions of system xC- give it a unique potential for influencing cell fate. 
System xC- activity can be either beneficial or destructive depending on the cellular 
properties.  If cells are susceptible to oxidative stress, increasing system xC- activity 
should be protective as it increases cystine uptake, which can contribute to increased 
antioxidative defense.  However, if the cells express high levels of glutamatergic 
receptors, it is likely that they will be sensitive to glutamate induced excitotoxicity.  
Thus, increasing system xC- activity might be destructive by increasing extracellular 
glutamate, which can potentially over-stimulate extrasynaptic glutamatergic receptors.   
In the present study, we used primary mixed neuronal and glial cell cultures 
derived from prenatal mouse cortex to investigate the effect of 48 hour FGF-2 treatment 
on neuronal survival/death.  We have previously demonstrated that 24 hour FGF-2 
treatment upregulated system xC- activity on astrocytes, but not neurons or microglia.  
We demonstrate here that after system xC- is upregulated for a prolonged period of time, 
neuronal death occurs due to system xC- mediated excitotoxicity.   
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MATERIALS AND METHODS 
Materials 
Timed pregnant Swiss Webster mice were obtained from Charles River 
Laboratories (Wilmington, DE).  Serum was from Atlanta Biologicals (Lawrenceville, 
GA).  FGF-2 was from Alomone Labs (Jerusalem, Israel).  14C-cystine was from 
PerkinElmer (Waltham, MA).  All other chemicals were obtained from Sigma (St. Louis, 
MO).   
 
Cortical cell cultures 
Mixed cortical cell cultures containing glial and neuronal cells were prepared 
from fetal (15-16 day gestation) mice as previously described (Lobner, 2000).  
Dissociated cortical cells were plated on 24-well plates coated with poly-D-lysine and 
laminin in Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied glutamine-
free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2 mM 
glutamine and glucose (total 21 mM).  Neuron-enriched cultures were prepared exactly as 
above with the addition of 10 µM cytosine arabinoside 48 hours after plating to inhibit 
glial replication.  In these cultures <1% of cells are astrocytes (Dugan et al., 1995; Rush 
et al., 2010).  Astrocyte-enriched cultures were prepared as described for mixed cultures 
except they are from cortical tissue taken from post-natal day 1-3 mice (Choi et al., 1987; 
Schwartz and Wilson, 1992; Rush et al., 2010).  Cultures were maintained in humidified 
5% CO2 incubators at 37°C.  Mice were handled in accordance with a protocol approved 
by our institutional animal care committee and in compliance with the Public Heath 
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service Policy on Humane Care and Use of Laboratory Animals.  All efforts were made 
to minimize animal suffering and reduce the number of animals used.   
 
Induction of neuronal death 
 All experiments were performed on cultures 13 days in vitro (DIV).  Cultures 
were exposed to different compounds for 48 hours in media as described for plating 
except without serum.   
 
Assay of neuronal death  
LDH release 
 Cell death was assessed in mixed cultures by the measurement of lactate 
dehydrogenase (LDH) released from damaged or destroyed cells, in the extracellular fluid 
48 hours after the beginning of the insult (Koh and Choi, 1987; Lobner, 2000).  Blank 
LDH levels were subtracted from insult LDH values and results normalized to 100% 
neuronal death caused by 500 µM NMDA, or 100% cell death caused by 20 µM of the 
calcium ionophore A23187, added 24 hours before the assay.  Control experiments have 
shown previously that the efflux of LDH occurring from either necrotic or apoptotic cells 
is proportional to the number of cells damaged or destroyed.  Glial cell death (assessed by 
trypan blue staining) was not observed in any of the current studies.  
 
MTT assay  
Cell survival was quantified by the measurement of the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to produce a dark blue 
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formazan product (Lobner, 2000).  MTT was added to each well 48 hours after the 
beginning of the insult to the cells (following removal of media for LDH assay).  After 
30-minute incubation, the medium was removed, and cells were dissolved in dimethyl 
sulfoxide. The formation of formazan was measured as the amount of reaction product by 
absorbance change at a wavelength of 590 nm by using a VersaMax tunable microplate 
reader (Molecular Devices, Sunnyvale, CA).  Levels of formazan formation from cultures 
exposed to 500 µM NMDA (100% neuronal death) were subtracted from insult formazan 
levels, and results were normalized to a sham wash.   
 
14C-cystine uptake 
System xC- mediated uptake of radiolabeled cystine was assayed as previously 
described with modifications (Liu et al., 2009).  FGF-2 was added to the serum 
containing media for the indicated durations.  Cultures were then washed into HEPES 
buffered saline solution and immediately exposed to 14C-cystine (0.025µCi/ml) for 20 
min.  Following 14C-cystine exposure, cultures were washed with ice cold HEPES 
buffered saline solution and dissolved in 250 µl sodium dodecyl sulfate (0.1%).  An 
aliquot (200 µl) was removed and added to scintillation fluid for counting.  Values were 
normalized to 14C-cystine uptake in untreated control on the same experimental plate.   
 
Statistical analysis 
Differences between test groups were examined for statistical significance by 
means of one-way ANOVA followed by the Bonferroni correction post-hoc test, with 
p<0.05 being considered significant.   
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RESULTS  
As reported previously, 24 hour FGF-2 treatment of mixed neuronal and glial 
cultures did not cause any cell death (Fig. 4.1.).  However, significant neuronal death was 
observed after 48 hours of FGF-2 treatment (Fig. 4.1.).   
 
 
FIGURE 4.1.  FGF-2 induced toxicity occurs in mixed neuronal and glial cultures 
after 48 hour treatment. 
Bars show % neuronal cell death (mean ± s.e.m., n = 24) quantified by measuring 
release of LDH, 24 and 48 hours after the beginning of treatment with 100 ng/ml FGF-2.  
* indicates significant difference from control.   
 
This neuronal death following FGF-2 treatment for 48 hours is only observed on 
mixed neuronal and glial cultures, but not neuronal-enriched cell cultures or glial-
enriched cell cultures (Fig. 4.2.), suggesting an interaction of glia and neurons may be 
necessary for FGF-2 induced neuronal death to occur.   
101 
 
FIGURE 4.2.  FGF-2 does not induce toxicity after 48 hour treatment on either 
neuronal-enriched cultures or astrocyte-enriched cultures. 
A: Neuronal-enriched culture. Bars show % neuronal death (mean ± s.e.m., n = 8) 
quantified by measuring release of LDH, 48 hours after the beginning of treatment with 
100 ng/ml FGF-2.  B: Astrocyte-enriched culture.  Bars show % cell death (mean ± 
s.e.m., n = 16) quantified by measuring release of LDH, 48 hours after the beginning of 
treatment with 100 ng/ml FGF-2.   
 
 We have shown previously that 24 hour FGF-2 treatment significantly increased 
system xC- activity selectively in astrocytes, with no effect on neuronal-enriched and 
microglial-enriched cultures (Liu et al., 2011).  To determine whether FGF-2 upregulated 
system xC- function is still present after 48 hours we measured 20 min cystine uptake 
following 48 hour FGF-2 treatment of astrocyte-enriched cultures.  FGF-2 treatment 
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doubled the cystine uptake, and the cystine uptake was mediated by system xC- as its 
inhibitor (s)-4-carboxyphenylglycine (CPG) completely blocked the increase (Fig. 4.3.).   
 
 
FIGURE 4.3.  FGF-2 induced increase in cystine uptake is mediated by system xC-. 
Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) for 48 hours, washed 
into a growth factor free media, and 14C-cystine uptake measured for 20 min with or 
without the system xC- antagonist (s)-4-carboxyphenylglycine (200 µM CPG).  Bars show 
% control (mean ± s.e.m., n = 6).  * indicates significant difference from control uptake. 
 
To assess whether system xC- is involved in the FGF-2 induced neuronal death, 
we tested the effects of the system xC- inhibitors CPG and sulfasalazine (SSZ) on 
neuronal death induced by 48 hour FGF-2 treatment.  Cotreatment of cells with either 
CPG or SSZ during the 48 hour FGF-2 incubation prevented the neuronal death (Fig. 
4.4.).  Because SSZ interferes with the LDH release assay, we used the MTT metabolism 
assay to assess cell survival.   
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FIGURE 4.4.  FGF-2 induced neuronal death is prevented by blocking system xC-. 
Mixed neuronal and astrocyte cultures were exposed to FGF-2 (100 ng/ml) with or 
without the system xC- antagonists (s)-4-carboxyphenylglycine (200 µM CPG) or 
sulfasalazine (300 µM SSZ) for 48 hours.  Bars show % cell survival (mean ± s.e.m., n = 
8) quantified by measuring MTT reduction, 48 hours after the beginning of the insult.  * 
indicates significant difference from control.   
 
System xC- mediates cystine uptake and glutamate release at the same time: 
cystine uptake contributes to GSH synthesis that can decrease oxidative stress, therefore, 
it is not likely to cause cell death; However, increasing glutamate release can lead to 
over-activation of glutamatergic receptors to cause excitotoxicity.  To test this possibility, 
we used various glutamatergic receptor antagonists to determine if they prevented FGF-2 
induced neuronal death.  We found that the AMPA receptor antagonist NBQX, but not 
the NMDA receptor blocker memantine, blocked the FGF-2 induced neuronal death (Fig. 
4.5A.).  This result is surprising because both NBQX and memantine block 48 hour direct 
glutamate toxicity (Fig. 4.5B.).   
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FIGURE 4.5.  Effects of the AMPA receptor antagonist NBQX and the NMDA 
receptor antagonist memantine on neuronal death induced by 48 hour 
exposure to FGF-2 or glutamate.   
A: FGF-2 (100 ng/ml) treatment induced toxicity is protected by blocking AMPA 
receptors.  B: Glutamate (15 µM) induced toxicity is protected by blocking AMPA or 
NMDA receptors.  NBQX: 7.5 µM 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-
2,3-dione.  MEM: 10 µM memantine.  Bars show % neuronal cell death (mean ± s.e.m., 
n = 12) quantified by measuring release of LDH, 48 hours after the beginning of the 
insult.  * indicates significant difference from control.  # indicates significant difference 
from FGF-2 or glutamate treated.   
 
One possibility for the results is that FGF-2 upregulates calcium permeable 
AMPA receptors making the neurons susceptible to AMPA receptor mediated toxicity.  
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However, we did not observe any protection against neuronal death when cultures were 
cotreated with FGF-2 and various concentrations of the selective calcium permeable 
AMPA receptor antagonist 1-naphthyl acetyl spermine (NASPM) (Fig. 4.6.).   
 
 
FIGURE 4.6.  FGF-2 induced toxicity is not mediated by calcium-permeable AMPA 
receptors.   
Mixed neuronal and glial cultures were exposed to FGF-2 (100 ng/ml) for 48 hours with 
or without calcium permeable AMPA receptor antagonist 1-naphthyl acetyl spermine 
(NASPM).  Bars show % neuronal cell death (mean ± s.e.m., n = 8) quantified by 
measuring release of LDH, 48 hours after the beginning of the insult.  * indicates 
significant difference from control.  
 
DISCUSSION 
This study examined the effect of FGF-2 on neuronal cell death in mixed neuronal 
and glial cultures and the involvement of its selective upregulation of system xC- on 
astrocytes.  System xC- has gained increasingly more attention because of its dual 
transport property.  System xC- provides cystine to the cells, which is the rate-limiting 
source for cysteine, which is one of the three components of glutathione, the major 
antioxidant in the brain (Dringen et al., 2000; Dringen and Hirrlinger, 2003).  In contrast, 
system xC- mediated glutamate release can lead to uncontrolled extracellular glutamate 
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and cause excitotoxicity (Fogal et al., 2007; Jackman et al., 2010).  Both oxidative stress 
and excitotoxicity are involved in various neurodegenerative diseases and psychiatric 
disorders.  Also, FGF-2 dysregulation is observed in acute and chronic neurological 
disorders (Gaughran et al., 2006; Terwisscha van Scheltinga et al., 2010; Zechel et al., 
2010).  Therefore, it is possible that changes in system xC- function may be responsible 
for some of the actions of FGF-2.   
Our previous data showed that 24 hour FGF-2 treatment resulted in an increase in 
cystine uptake through system xC- on astrocytes, but with no effect on neuronal and 
microglial cystine uptake (Liu et al., 2011).  FGF-2 treatment mediated increase of 
system xC- was mediated through activation of FGFR1 and required both MEK/ERK and 
PI3 kinase pathway activations (Liu et al., 2011).  All of these cellular events happened 
without significant neuronal toxicity.  However, after 48 hour FGF-2 treatment, 
significant neuronal cell death began to occur.  This neuronal death was blocked by the 
system xC- antagonists CPG and SSZ.   
The role of system xC- in cell death has been investigated in different cell types 
and under different conditions.  Inhibition of system xC- has been shown to be harmful to 
system xC- expressing cells.  Oxidative glutamate toxicity was first described on 
immature neuronal cultures, in which system xC- is the major route of cystine uptake 
(Murphy et al., 1989; 1990).  Applying high concentrations of glutamate (millimolar 
range) to these immature neurons led to GSH depletion and eventually cell death from 
oxidative stress (Miyamoto et al., 1989; Murphy et al., 1989; Murphy and Baraban, 
1990).  Under these circumstances, increasing system xC- levels would likely be 
protective.   
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However, increasing system xC- function is not always protective.  It seems that 
increasing system xC- function in certain population of cells can be toxic to the 
surrounding cells.  Primary microglia cultured in physiological extracellular 
concentrations of cystine and glutamine have been shown to be able to release enough 
glutamate through system xC- to kill surrounding neurons (Piani and Fontana, 1994) 
(Domercq et al., 2007).  Activation of these microglia by bacterial components enhanced 
system xC- mediated glutamate release, which was prevented by blocking protein 
synthesis (Piani and Fontana, 1994).  Similarly, the increase in xCT expression in 
microglia induced by lipopolysaccharide treatment led to increased system xC- mediated 
release of glutamate, causing excitotoxicity to cocultured oligodendrocytes (Domercq et 
al., 2005).  This toxicity was decreased by blocking AMPA receptors with CNQX 
(Domercq et al., 2005).  This result is similar to what we have observed on our primary 
mixed neuronal and glial cultures.  The difference is that oligodendrocytes are normally 
sensitive to AMPA receptor toxicity (McDonald et al., 1998; Takahashi et al., 2003), 
while in cortical neurons, glutamate induced excitotoxicity is normally mediated 
primarily by activation of NMDA receptors (Choi et al., 1987; Choi, 1998).   
Similar to microglia, selectively increasing system xC- on astrocytes with IL-1β 
can also lead to increased glutamate release, which potentiates srounding neuronal death 
induced by hypoglycemia and hypoxia (Jackman et al., 2010; 2012), both of which are 
well-known to kill neurons in a process that involves over-activation of glutamatergic 
receptors (Snider et al., 1998; Czyz et al., 2002).  The neuronal death in these conditions 
was largely attenuated by blocking NMDA receptors with the selective NMDA receptor 
open channel blocker MK-801, and was also blocked by the system xC- inhibitor CPG 
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(Fogal et al., 2007; Jackman et al., 2010; 2012).  Our data shows that FGF-2 treatment, 
like IL-1β, selectively increases system xC- activity on astrocytes (Liu et al., 2011).  But 
FGF-2 by itself induced neuronal cell death after system xC- activity was upregulated for 
48 hours.  Also, the pharmacological profile of the excitotoxicity was different from non-
FGF-2 treated neurons.  We showed that, while neuronal death induced by direct 
exposure of cultures to glutamate was blocked by either NMDA or AMPA receptor 
antagonists, FGF-2 induced neuronal death was only attenuated by the AMPA antagonist.   
FGF-2 has been shown to be able to change neuronal expression of both NMDA 
and AMPA receptors, and to alter sensitivity to NMDA receptor mediated toxicity both in 
vitro and in vivo.  A study conducted on cerebellar granule cells reported that FGF-2 
treatment caused a time-dependent decrease in expression of NMDA receptor subunits 
GluN2A and GluN2C with a decrease of NMDA-evoked calcium influx, while GluN1 
and GluN2B levels were not changed (Brandoli et al., 1998).  Also, FGF-2 pretreatment 
protected striatal neurons from NMDA receptor mediated toxicity (Freese et al., 1992).  
Systematic administration of FGF-2 protected against intrastriatal injection of NMDA 
(Nozaki et al., 1993a; 1993b).  FGF-2 treatment enhanced the rate of NMDA receptor 
inactivation in response to calcium influx in hippocampal neurons (Boxer et al., 1999).  
FGF-2 treatment decreased NMDA receptor levels in hippocampal cell cultures and 
elevations in intracellular calcium levels after glutamate exposure compared to non-FGF-
2 treated cells (Mattson et al., 1993).  FGF-2 treatment has been shown to increase 
AMPA receptor subunit GluR1 levels in the same cultures, without altering GluR2, 
GluR3, and GluR4 levels (Cheng et al., 1995).  This suggested the possibility that FGF-2 
increased the levels of GluR2 subunit lacking AMPA receptors, which have calcium 
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permeability (Bannerman et al., 2007).  However, the selective antagonist of these 
channels, NASPM, failed to offer protection in our study.  At concentrations above 5 µM, 
NASPM began to induce some toxicity by itself.  The IC50 of NASPM for calcium-
permeable AMPA receptors is 0.33 µM (Brackley et al., 1993; Koike et al., 1997).  
Therefore, the 5 µM concentration that was not toxic should have been an effective 
concentration.  Therefore, it is possible that the FGF-2 treatment induced increased 
glutamate release from system xC- causes an AMPA receptor specific neuronal death 
because of attenuated NMDA receptor mediated toxicity induced by FGF-2 treatment.   
FGF-2 was a potential candidate for the treatment of stroke as it was shown to 
reduce ischemic damage, as well as, promote recovery and regeneration in multiple in 
vitro and animal models (Nozaki et al., 1993b; Rosenblatt et al., 1994; Song et al., 2002; 
Watanabe et al., 2004).  However, in human clinical trials, FGF-2 not only failed to show 
any beneficial effect in treated patients compared to control patients, it actually increased 
the mortality rate in treated patients (Clark et al., 2000; Bogousslavsky et al., 2002).  The 
reasons for FGF-2 being beneficial in animal models but not in human trials are not yet 
fully understood.  Given that FGF-2 can increase system xC- activity, and the dual 
functions of system xC-, it is not surprising that FGF-2 can have varying effects on 
cerebral ischemia.   
FGF-2 administration has been shown to be beneficial in rodent studies in other 
disease models, such as depression (Turner et al., 2008c) and Parkinson disease (Hsuan et 
al., 2006).  It is possible that these beneficial effects may be mediated by the FGF-2 
effect on system xC-, which leads to enhanced glutathione synthesis.  However, again 
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taking into account the dual actions of system xC-, the effects of long-term treatment with 
FGF-2 must be rigorously studied.   
 
CONCLUSIONS 
The dual amino acid transport function allows system xC- regulate intracellular 
cystine and extracellular glutamate levels at the same time.  Cystine taken up is broken 
down immediately to cysteine, which is a substrate for glutathione synthesis and protein 
synthesis.  While increasing cystine uptake can be protective by increasing the cells’ 
antioxidative defense, glutamate released at the same time can potentially cause toxicity 
by over activating glutamatergic receptors.  We show here that the net effect of long-term 
upregulation of system xC- selectively on astrocytes in mixed neuronal and glial cultures 
by FGF-2 treatment is negative.  That is, the excitotoxicity component dominates, leading 
to neuronal death.   
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CHAPTER V 
 
 
 
 
GENERAL DISCUSSION 
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System xC- mediates cystine and glutamate exchange (Sato et al., 1999), thus it is 
involved in both regulating extracellular glutamate and intracellular GSH due to its dual 
amino acid transport function.  Both abnormal glutamate transmission and chronic 
oxidative stress have been indicated to contribute to neurodegenerative diseases, such as 
amyotrophic lateral sclerosis, stroke, traumatic spinal cord/brain injury, Alzheimer’s 
disease and Parkinson’s disease (Dugan and Choi, 1994; Andersen, 2004), as well as 
psychiatric disorders such as addiction (Tsai et al., 1998) and schizophrenia (Pérez-Neri 
et al., 2006).  Therefore, it seems likely that alterations in system xC- function may play a 
role in these diseases.  To begin to resolve this question, a series of studies were 
conducted to find out how system xC- is involved in brain cell health in primary cortical 
cell cultures.  We found that the environmental neurotoxin BMAA can compete with 
cystine at system xC- leading to both oxidative stress and excitotoxicity, that FGF-2 can 
upregulate system xC- selectively on astrocytes, and that the upregulation of system xC- 
by FGF-2 treatment may be responsible for AMPA receptor specific neuronal death 
caused by 48 hour treatmentFGF-2 .  Following is a discussion of some of the issues that 
arose during these studies.   
 
INTERACTION OF FGF-2 AND BMAA ON NEURONAL DEATH 
Since both BMAA and FGF-2 have actions on system xC-: FGF-2 upregulates 
system xC- function (Liu et al., 2011) and BMAA competes with cystine at system xC- 
(Liu et al., 2009), we examined whether FGF-2 pretreatment alters BMAA toxicity.  
FGF-2 pretreatment for 24 hours changed the concentration response of BMAA toxicity 
(Fig. 5.1).  At low concentrations, BMAA toxicity was potentiated by FGF-2 
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pretreatment, while at high concentrations, FGF-2 pretreatment protected neurons from 
BMAA toxicity.   
 
 
FIGURE 5.1.  Concentration response of BMAA induced neuronal death after FGF-
2 pretreatment. 
Mixed neuronal and glial cultures were pretreated with 100 ng/ml FGF-2 for 24 hours 
before various concentrations of BMAA were added.  Media was sampled for LDH assay 
24 hours after the beginning of the BMAA insults.  Bars show % neuronal cell death 
(mean ± s.e.m., n= 8) quantified by measuring release of LDH.  * indicates significant 
difference from control (no BMAA). 
 
The mechanism to explain this result may be very complicated, since both BMAA 
and FGF-2 have multiple effects on cells.  BMAA can decrease glutathione by decreasing 
cystine uptake (Liu et al., 2009), inhibiting glutathione synthesis (Esterhuizen-Londt et 
al., 2011), and potentially be incorporated into glutathione.  With bicarbonate present, 
BMAA mimics glutamate and directly activates glutamatergic receptors (Weiss and Choi, 
1988; Rao et al., 2006; Lobner et al., 2007).  FGF-2, as a growth factor, has a wide range 
of effects on both neurons and glia (Beck, 1994; Eckenstein, 1994; Ghosh and Greenberg, 
1995; Temple and Qian, 1995; Grothe and Wewetzer, 1996; Ford-Perriss et al., 2001; 
Reuss and Bohlen und Halbach, 2003; Mudò et al., 2009).   
114 
If we consider system xC- as the main mediator of the effects of both compounds, 
the most likely explanation for the data is as follows.  At low levels of BMAA, when 
system xC- is upregulated by FGF-2 pretreatment, BMAA drives increased glutamate 
release from system xC-, which exacerbates BMAA toxicity by over activating 
glutamatergic receptors.  The result could also be explained by a different mechanism: 
FGF-2 pretreatment may potentiate low level BMAA toxicity by upregulating system xC- 
allowing more BMAA to enter the cells and through inhibition of enzymes or 
incorporation into glutathione act to decrease cellular glutathione levels.    However, at 
high levels of BMAA, excitotoxicity caused by direct activation of glutamatergic 
receptors by BMAA is already maximized, and no further excitotoxicity can be induced, 
but elevated system xC- function by FGF-2 pretreatment provides cells with more cystine 
which strengthens antioxidative defense, thus providing protection against BMAA 
toxicity.   
Due to the complicated actions of both BMAA and FGF-2, and the lack of direct 
scientific implication of their interaction occurring, no further studies were performed 
concerning BMAA and FGF-2 interactions.   
 
CONTROVERSIES REGARDING BMAA 
 In chapter two of this thesis we examined the mechanisms of BMAA toxicity and 
found that one novel way in which it kills neurons is through actions on system xC-.  It 
not only competitively inhibits cystine uptake leading to glutathione depletion, but also 
increases glutamate release, causing excitotoxicity.  This is potentially a very important 
result because it provides a novel mechanism for BMAA toxicity, but it is only important 
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if BMAA does play a role in neurodegenerative diseases.  In this section, we will explore 
some of the controversies regarding the potential role of BMAA in neurodegenerative 
diseases.   
 
Is BMAA a potent neurotoxin? 
One major question concerning BMAA is whether it can cause neuronal death at 
low enough concentrations to make it a potential factor in neurodegenerative diseases.  
Studies in cortical cell culture have shown that very high BMAA concentrations (1 - 3 
mM) are required to induce neuronal death (Ross et al., 1987; Weiss and Choi, 1988; 
Weiss et al., 1989b; Lobner et al., 2007).  One potential mechanism by which BMAA 
may be involved in neurodegenerative diseases is that it is not acting as the sole cause of 
the disease, but may act in concert with other environmental or genetic factors.  In 
support of this possibility it was found that BMAA, at concentrations as low as 10 µM, 
potentiated amyloid-β and 1-methyl-4-phenylpyridinium ion (MPP+) toxicity, models of 
Alzheimer’s and Parkinson’s disease, respectively (Lobner et al., 2007).   
We also looked into the possibility of BMAA causing selective toxicity of 
specific vulnerable populations of neurons.  Mesencephalic and septal primary cultures 
were prepared to study the death of dopaminergic neurons and cholinergic neurons, 
which are associated with Parkinson’s disease and Alzheimer’s disease, respectively.  
The small percentage (0.1%-1%) of dopaminergic and cholinergic neurons present in the 
two cultures allowed for the analysis of death of these specific cell populations at the 
same time as death of the total neuronal population.  That is, the total neuronal death was 
assessed by the LDH release assay, and then the cells were fixed and stained, with the 
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number of dopaminergic or cholinergic cells counted.  In mesencephalic cultures there 
was no difference between the sensitivity of the total neuronal population and the 
dopaminergic neurons to BMAA toxicity (Fig. 5.2A).  In contrast, in the septal cultures, 
the cholinergic neurons were significantly more sensitive than the total neuronal 
population at both the 30 and 300 µM BMAA concentrations (Fig. 5.2B).  The LC50 
values calculated by nonlinear regression analysis were: dopaminergic neurons – 304 
µM; total mesencephalic neurons – 241 µM; cholinergic neurons – 32 µM; total septal 
neurons – 586 µM.   
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FIGURE 5.2.  Cholinergic, but not dopaminergic neurons are selectively sensitive 
to BMAA toxicity. 
BMAA concentrations of 3 µM, 30 µM, 300 µM, and 1 mM were present for 24 hours. 
The cell counting data shows % dopaminergic (A) or cholinergic (B) neuronal death 
(mean ± SEM, n = 8) quantified by counting the number of TH or ChAT-positive neurons.  
The LDH release data shows % total neuronal cell death (mean ± SEM, n = 8). * 
indicates significant difference between the LDH release and cell counting data. 
 
 To determine the mechanism of BMAA toxicity in septal cultures we assayed the 
protective effects of the NMDA receptor antagonist MK-801, the AMPA/kainate receptor 
antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), 
and the free radical scavenger trolox on both total neural death and specific cholinergic 
neuronal death.  To match the levels of death, 500 µM BMAA was used for total septal 
neuronal death, and 300 µM BMAA for cholinergic neuronal death.  For total septal 
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neuronal death, protection was provided by MK-801 and trolox, but not NBQX (Fig. 
5.3A.).  This is consistent with our previous results in cortical cultures where we found 
evidence for both NMDA receptor and free radical mediated neuronal death (Lobner et 
al., 2007).  In contrast, the death of cholinergic neurons was not attenuated by MK-801 or 
trolox, but was decreased by NBQX (Fig. 5.3B.).   
 
 
FIGURE 5.3.  MK801 (10 µM) and trolox (100 µM) provide protection against BMAA 
toxicity to total septal neurons (A), while NBQX (20 µM) provides protection of 
cholinergic neurons (B).   
Bars show % neuronal cell death (mean + SEM, n= 12) quantified by measuring release 
of LDH (A) or counting of cholinergic neurons (B). * indicates significant difference from 
control.   
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In cortical cultures, where at least 1mM BMAA is required to induce general 
neuronal death (Ross et al., 1987; Weiss and Choi, 1988; Weiss et al., 1989b; Lobner et 
al., 2007).  However, death of the small subpopulation of NADPH-diaphorase cells 
occurs at a BMAA concentration of 100 µM, because these NADPH-diaphorase cells are 
characterized by high levels of calcium permeable AMPA receptors (Weiss et al., 1989b).  
Similarly, motor neurons, which are also characterized by calcium permeable AMPA 
receptors, have also been shown to be highly sensitive to BMAA toxicity, with death 
occurring at a concentration of 30 µM (Rao et al., 2006).  Furthermore, like NADPH-
diaphorase cells, this death is mediated by activation of AMPA/kainate receptors (Weiss 
et al., 1989a; Carriedo et al., 1995).  Cholinergic neurons have also been shown to 
possess high levels of calcium permeable AMPA receptors (Yin et al., 1994).  The results 
indicated that neurons containing high levels of calcium permeable AMPA receptors are 
more sensitive to BMAA toxicity.  However, the protective effect of NBQX was not 
complete, suggesting that other mechanisms of toxicity are also involved.   
Rapid electrophysiological studies have established that the effects of BMAA on 
NMDA receptors are due to direct actions on the receptor (Weiss et al., 1989b; Lobner et 
al., 2007).  BMAA has been shown to bind to AMPA receptors (Rakonczay et al., 1991; 
Cucchiaroni et al., 2010), and cause convulsions when injected into the lateral ventricle 
of rats that are blocked by AMPA antagonists (Matsuoka et al., 1993).  In our lab, we 
found that BMAA is a substrate for system xC-, and through this action drives glutamate 
release (Liu et al., 2009).  Therefore, an alternative explanation for BMAA being a direct 
AMPA receptor agonist is that BMAA may stimulate the release of endogenous 
glutamate, which activates the glutamatergic receptors.  In this case, the presence or 
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absence of calcium permeable AMPA receptors would determine the sensitivity of the 
cells to the toxicity of the endogenous glutamate.   
The importance of these results is that they show that specific, and functionally 
important, populations of neurons are sensitive to BMAA toxicity at concentrations that 
are much lower than the general cortical neuronal population, making it more likely that 
BMAA plays a role in neurodegenerative diseases where cell death of specific 
populations occurs.   
 
Measurement of BMAA 
Another area of controversy is the detection and quantification of BMAA in 
tissues.  There are labs that have successfully measured and quantified it in multiple types 
of tissues (Cox and Sacks, 2002; Murch et al., 2004a; Pablo et al., 2009), while there are 
also labs that have failed to detect BMAA in similar systems (Montine et al., 2005; 
Snyder et al., 2009).  Different methods used in these studies may be responsible for the 
lack of detection (Crimmins and Cherian, 1997).  A recent review by Steve Cohen of 
Waters Corp, the developer of multiple amino acid detection methods, suggested that 
using HILIC columns with tandem mass spectrometry, the method used by all of the 
investigators not detecting BMAA, may not be detecting BMAA because of the high 
level of ionization suppression due to much higher concentrations of other matrix 
components (Cohen, 2012).  Another complication is that it has been shown that the 
majority of BMAA in tissue is protein bound (Murch et al., 2004b).  This may be 
occurring through misincorporation into cellular proteins by BMAA being mischarged to 
the tRNAs (unpublished data).  Therefore, the processing method of samples becomes 
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important in whether BMAA is detected (Crimmins and Cherian, 1997; Murch et al., 
2004b).   
 
BMAA in animal models 
Several studies have been conducted to examine BMAA effects in vivo.  
Macaques were fed 100-350 mg/kg BMAA daily for 13 weeks, after which 
corticomotoneuronal dysfunction, Parkinsonian features and behavioral abnormalities 
were observed (Spencer et al., 1987).  However, the study was criticized for the high 
levels of BMAA that was tested (Duncan et al., 1990).  Intracerebroventricular 
administration of 0.5 mg/day of BMAA to rats up to 60 days old caused cholinergic cell 
degeneration as early as 16 days after BMAA administration and general cortical 
neuronal damage after 40 days (Rakonczay et al., 1991).  With the same BMAA 
administration, behavioral changes such as splay, jerking movements, and rigidity were 
elicited 6 days after administration (Rakonczay et al., 1991; Matsuoka et al., 1993).  
Although the symptoms elicited by BMAA administration are not exactly the same as 
observed in ALS-PDC, considering the difficulty in modeling the effects of chronic 
BMAA exposure, it was encouraging to observe neuronal toxicity and behavior changes 
following BMAA administration.  However, these studies involve intracerebroventricular 
injection, while exposure in humans is through ingestion.  There are a number of studies 
that failed to observe any behavioral responses following oral intake of BMAA.  Force-
feeding a total of 15.5 g/kg (500mg/kg or 1000 mg/kg doses) of BMAA to Cynomolgus 
monkeys for 11 weeks did not induce any behavior changes, nor any neurotoxicity in the 
cerebral cortex (Perry et al., 1989).  In another study, feeding adult mice 28 mg/kg of 
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BMAA per day for 30 days caused no motor, cognitive or neuropathological changes 
(Cruz-Aguado et al., 2006).  Therefore, whether chronic BMAA administration induces 
any behavioral or neuropathological changes is still controversial and requires more 
study.  One problem is that humans may be exposed to BMAA for decades, which cannot 
be mimicked in animal models.  Also, animal studies have involved administration of 
BMAA to young, healthy animals, which does not mimic the complex changes occurring 
in the aging human brain, or interactions with other environmental and genetic factors.    
 
Is action on system xC- an important mechanism of BMAA toxicity? 
We showed that along with the already known action of BMAA of activating 
glutamatergic receptors, BMAA also acts as a substrate for system xC- decreasing cystine 
uptake and increasing glutamate release.  Thus, by acting at system xC-, BMAA can 
cause both oxidative stress and excitotoxicity, both of which occur during 
neurodegenerative diseases.  This makes it an attractive mechanism to explain BMAA’s 
potential role in neurodegenerative diseases.  BMAA producing cyanobacteria exist 
ubiquitously, and it can get into the food supply, by accumulation in fish, crabs, and 
oysters (Banack et al., 2007; Cox et al., 2009; Brand et al., 2010; Jonasson et al., 2010; Li 
et al., 2010).  Therefore, it is important to study the potential threats of BMAA and 
understand the role of system xC- in its mechanism of toxicity.   
 
REGULATION OF SYSTEM XC- BY FGF-2 
 In chapter three of this thesis, we presented data showing the novel action of 
FGF-2 on astrocytes: increasing system xC- function (Liu et al., 2011).  This effect was 
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mediated by FGFR1, and required activation of both the PI3K/Akt and MEK/ERK 
pathways.  It has been well accepted that FGF-2 is involved in many aspects of central 
nervous system function and regulation (Eckenstein, 1994; Dono, 2003; Reuss and 
Bohlen und Halbach, 2003).  This new action of FGF-2 might provide insights into some 
of its effects in the brain.   
 
FGF-2 in the central nervous system 
FGF-2 is a well studied growth factor that has been shown to be more prevalent in 
the central nervous system than the peripheral organs (Ledoux et al., 1992).  By 
interacting with four cell surface tyrosine kinase FGF receptors and acting through 
several intracellular pathways, FGF-2 has been shown to be involved in development 
(Ohkubo et al., 2004), adult neurogenesis (Mudò et al., 2009), and tissue repair (Reuss 
and Bohlen und Halbach, 2003).  FGF-2 may be involved in acute and chronic 
neurodegenerative diseases such as stroke (Alzheimer and Werner, 2002) and 
Alzheimer’s disease (Mark et al., 1997).  FGF-2 expression can be changed.  Processes 
such as injury, stress, seizures, learning and memory all have been shown to increase 
FGF-2 expression (Dono, 2003; Fumagalli et al., 2005).  FGF-2 dysregulation has been 
suggested in schizophrenia (Terwisscha van Scheltinga et al., 2010), stress (Molteni et 
al., 2001; Frank et al., 2007), addiction (Flores and Stewart, 2000), major depression 
(Evans et al., 2004), as well as traumatic brain injury (Mellergård et al., 2012).  Its 
important role in neurogenesis and tissue repair in adult makes FGF-2 an attractive 
candidate for treatment of various neurodegenerative disorders.   
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FGF-2 and oxidative stress 
There is substantial evidence indicating that system xC- is induced when cells 
suffer from oxidative stress or low GSH (Sato et al., 2004; Seib et al., 2011; Lewerenz et 
al., 2012; Bridges et al., 2012b).  The effects of FGF-2 on oxidative stress are unclear.  It 
has been shown that FGF-2 potentiates oxidative stress mediated neuronal death (Lobner 
et al., 2003).  However, FGF-2 has also been shown to be protective against oxidative 
stress mediated toxicity (Yang and de Bono, 1997; Yamada et al., 2001).  Regarding the 
possibility that the FGF-2 upregulation of system xC- that we observed was mediated by 
oxidative stress, co-treatment of the free radical scavenger trolox with FGF-2 did not 
prevent the increased system xC- mediated cystine uptake induced by FGF-2 treatment 
(Fig. 5.4.).  We have shown previously that trolox blocks methylmercury induced 
increased system xC- activity, which we believe was mediated by decreased 
glutathione/oxidative increased stress (Rush et al., 2012b).  Therefore, it is unlikely that 
the FGF-2 treatment induced increase in system xC- function was mediated by oxidative 
stress.   
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FIGURE 5.4.  FGF-2 induced increase in cystine uptake is not oxidative stress 
dependent. 
Astrocyte-enriched cultures were exposed to FGF-2 (100 ng/ml) with or without the free 
radical scavenger trolox (100 µM) for 24 hours, washed into a growth factor free media, 
and 14C-cystine uptake measured for 20 min.  Bars show % control (mean ± s.e.m., n = 
6).  * indicates significantly different from control uptake.   
 
FGF-2 and glutamate 
It is well accepted that there is an interaction between FGF-2 and glutamate 
neurotransmission.  FGF-2 is required for normal generation of glutamatergic projections 
in vivo (Korada et al., 2002).  Decreased glutamatergic neurons and glutamatergic 
transmissions were reported in FGF-2 deficient mice (Fadda et al., 2007).  Mice carrying 
a mutation in fgfr1 gene showed decreased glutamatergic transmission in frontal and 
temporal cortex (Shin et al., 2004).  FGF-2 also promotes glial expression of glutamate 
transporters (Figiel et al., 2003), and reduced NMDA receptor activity in vivo (Fumagalli 
et al., 2004).   
We also investigated whether glutamate has an effect on system xC- activity.  We 
used 50 µM bicuculline, a GABA(A) receptor blocker, and 2.5 µM 4-AP, a potassium 
channel blocker, to cause the presynaptic release of neurotransmitters and selectively 
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activate synaptic receptors.  In our primary cortical cultures, the majority of the synapses 
are glutamatergic synapses.  Our preliminary data suggested that synaptic glutamate 
release can lead to increased cystine uptake within 20 min (Fig. 5.5.), and the cystine 
uptake was mediated through system xC- because it was CPG sensitive (Fig. 5.5.).  The 
effect, while significant, was small and variable among different plates.  When we 
continued these studies by testing the effect of various glutamatergic receptor antagonists 
on the effect of bicuculline/4-AP of increasing cystine uptake, the increase in cystine 
uptake disappeared.  Also, we were unable to determine whether the increase of system 
xC- function is caused by synaptic glutamate release.  Therefore, this line of study was 
not pursued further.   
 
 
FIGURE 5.5.  Short-term synaptic glutamate release increases system xC- activity.   
Mixed neuronal and glial cultures were exposed to (-)bicuculline methochloride (Bic, 50 
µM) and 4-aminopyridine (4-AP, 2.5 µM) for 20 min, then 14C-cystine is added to the 
media, and 14C-cystine uptake is measured for 20 min.  Bar show % control 
(mean±s.e.m., n=24).  * indicates significantly different from control uptake.   
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TOXICITY OF FGF-2 MEDIATED BY SYSTEM XC- 
Despite the numerous reports of FGF-2 as a neuroprotective growth factor 
(Alzheimer and Werner, 2002), cytotoxic effects of FGF-2 have also been reported.  
FGF-2 inhibits growth of cultured breast cancer cells (Johnson et al., 1998; Wang et al., 
1998), Ewing’s sarcoma cells (Schweigerer et al., 1987), and human neuroblastoma cells 
(Russo et al., 2004).  In Ewing’s sarcoma tumors, the cytotoxic effect of FGF-2 is 
mediated through the same pathways that were associated with FGF-2 induced cell 
proliferation (Kim et al., 2004; Russo et al., 2004; Williamson et al., 2004; Ma et al., 
2008).  48 hour treatment of FGF-2 inhibits Ewing’s sarcoma growth by inducing cell 
death in three different cell lines (Sturla et al., 2000; Ma et al., 2008).  FGF-2 also 
inhibits Ewing’s sarcoma growth in vivo (Sturla et al., 2000).  Overexpressing FGF-2 in 
mice reduces chondrocyte proliferation by increasing apoptosis (Sahni et al., 2001).   
 We also observed significant neuronal death 48 hours after FGF-2 treatment, 
which was associated with upregulation of system xC- activity.  Blocking either system 
xC- or AMPA receptors eliminated the neuronal cell death, suggesting glutamate exported 
from astrocytic system xC- contributes to the neuronal death.  However, we cannot 
exclude the possibility that the neuronal toxicity was due to FGF-2 sensitizing the 
neurons to normal glutamate release from system xC-.  An AMPA receptor antagonist, 
NBQX, but not an NMDA receptor antagonist, MEM, blocked the FGF-2 induced 
neuronal death.  This profile of toxicity is different from non-FGF-2 treated cells, in 
which low level glutamate exposure causes a similar level of neuronal death, but it is 
prevented by either AMPA or NMDA receptor antagonists.  We could not use the more 
potent NMDA receptor antagonists (2R)-amino-5-phosphonovaleric acid (APV) or MK-
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801 because they cause cell death by themselves, even at low concentrations, after 48 
hours (data not shown).  Bath incubation of glutamate is believed to activate extracellular 
receptors, which is likely similar to glutamate released from system xC-.  Therefore, FGF-
2 is in some way altering the type of excitotoxicity that occurs to the neurons.  To 
determine what FGF-2 changes in terms of response to glutamate, detailed studies would 
need to be carried out examining whether the levels of NMDA and AMPA receptors were 
changed.  This could be done by western blotting, examining the levels of NMDA and 
AMPA receptor subunits.  Furthermore, electrophysiological studies would be needed to 
examine whether functional changes in receptors occurred.  Fura-2 studies could also be 
carried out to examine whether calcium influx was changed by FGF-2 treatment.  It is 
also possible that the changes in glutamate receptor mediated toxicity are due to changes 
in the intracellular signaling cascade downstream of receptor activation.   
We made several attempts to measure whether there was elevated glutamate 
accumulating in the culture media following 48 hour FGF-2 treatment.  DIV 13 astrocyte-
enriched cultures were washed into fresh media, then following 48 hour exposure to 
FGF-2 or not (CTRL), bathing media from the cell cultures was collected and assayed for 
glutamate by HPLC.  The media used for such long-term exposure was requred to be a 
complex media we call MS, which contains more than 100 µM concentrations of 8 amino 
acids including cystine.  Astrocyte-enriched cultures were used because in mixed cultures 
neuronal death would occur at this time point, and the dead neurons would have released 
large amounts of glutamate.  Since the FGF-2 effect on system xC- occurs on astrocytes, 
the effect should be observed in the astrocyte-enriched cultures.  Two HPLC methods 
were tried to quantitate glutamate: phenylisothiocyanate (PITC) derivatization with 
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ultraviolet detection on an Agilent 1100 HPLC and fluorescence detection with 
ophthaldehyde pre-column derivitization on a Shimadzu LC10AD HPLC.  However, 
because the experiments were done in a complex media, there was an interfering peak 
where glutamate was to be measured.  Both a Hypersil-ODS reverse phase column and a 
Synergi Hydro-RP column were tested with the PITC derivatization with ultraviolet 
detection method in an attempt to separate the interfering peak from the glutamate peak. 
Also various mobile phases and flow rates were tested.  Although the new column, and 
using a slower flow rate appeared to give us better separation, it significantly decreased 
the sensitivity for detection of glutamate (more than 10 times less sensitive).  Since we 
are detecting glutamate in a large amount of extracellular media compared to that of the 
restricted space among the attached cells (with an estimated 1:1000 dilution), the 
glutamate concentration in the extracellular media is very low.  Furthermore, it is not 
known whether FGF-2 treatment changes the glutamate uptake efficiency.  Therefore, we 
were unable to determine the extracellular glutamate levels under these conditions.  
We cannot exclude the possibility of FGF-2 treatment changing neuronal 
susceptibility to normal extracellular glutamate levels.  One of the possibilities being that 
FGF-2 treatment changes the astrocytes’ ability to release cysteine-containing molecules, 
which in turn, selectively decreases glutathione levels in neurons, causing them to be 
susceptible to any insult, including glutamate levels that does not cause death to healthy 
neurons.  This hypothesis could be tested by measuring thiols by HPLC in the culture 
media of mixed neuronal and glial cultures.   
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IS SYSTEM XC- ACTIVITY TOXIC TO NEURONS? 
In this dissertation, we have shown that BMAA can contribute to neuronal death 
by acting at system xC-.  Also, that prolonged FGF-2 treatment can upregulate system xC- 
and cause a system xC- function dependent neuronal toxicity.  As knowledge of the 
function of system xC- expands, and the interest in targeting this system as a treatment for 
various neurodegenerative diseases and psychiatric disorders increases, it is important to 
understand the potential damage that system xC- activity can cause.  Currently, it is clear 
that for cells that mainly rely on system xC- to take up cystine for the production of 
glutathione, blocking system xC- function can be toxic (Murphy et al., 1989).  The 
question remains whether the glutamate exchanged out of these cells by system xC- is a 
threat to surrounding cells.  Glioma cells have increased system xC- function, as well as 
decreased glutamate uptake, leading to increased extracellular glutamate which can cause 
toxicity to the surrounding neurons (Ye and Sontheimer, 1999; Sontheimer, 2003; 2008; 
Ogunrinu and Sontheimer, 2010).  Both FGF-2 (Liu et al., 2011) and IL-1β (Fogal et al., 
2007) upregulate system xC- function selectively on astrocytes.  Long-term FGF-2 
treatment causes a system xC- function dependent, and AMPA receptor specific, neuronal 
death.  While IL-1β treatment potentiates hypoxia and glucose deprivation induced 
neuronal death through a system xC- activity dependent mechanism (Fogal et al., 2007; 
Jackman et al., 2012).  Another example of increased system xC- function is activated 
microglia, which release enough glutamate through system xC- to cause toxicity to the 
surrounding neurons (Domercq et al., 2007).  In all of these studies, along with the 
involvement of system xC-, the neurons are under stress: hypoxia, glucose deprivation, or 
stimulation by growth factors or cytokines.  Therefore, while it is clear that enhanced 
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system xC- activity on non-neuronal cells can potentiate neuronal death when the neurons 
are compromised, it is uncertain whether glutamate release from system xC- can cause 
neuronal death under normal conditions.  
 
QUESTIONS REGARDING SYSTEM XC- STUDIES 
Molecular properties of system xC- 
Northern blot has shown three different xCT transcripts (12, 3.5 and 2.5 kb) in 
cultured macrophages and HT22 cells, as well as in various mouse organ tissues (Sato et 
al., 1999; 2001; 2004; 2005; Lewerenz et al., 2006; Taguchi et al., 2007).  They may 
represent alternative splicing or alternative polyadenylation (Sato et al., 1999; Lewerenz 
et al., 2006).  While all of these transcripts are inducible to a similar extent in culture 
(Sato et al., 1999), they have a different distribution pattern. The 3.5 and 2.5 kb 
transcripts were predominantly seen in macrophages, while the 12 kb RNA transcript was 
found in mouse brain, but not in peripheral organs such as heart, lung, liver, and kidney 
(Sato et al., 1999; Bassi et al., 2001; Sato et al., 2002).  Human ovarian cancer cell lines 
(Okuno et al., 2003), hamster kidney cells (Sasaki et al., 2002), and cultured rat 
astrocytes (Gochenauer and Robinson, 2001)were shown to exclusively express the 12 kb 
transcript of xCT.   
The predicted amino acid sequence from cDNA for xCT would be a protein of 
502 amino acids with a relative molecular mass of 55.5 kDa (Sato et al., 1999).  
However, in reality, xCT with various molecular masses have been reported.  The 55kDa 
protein is observed both in brain in vivo and in cortical neuronal stem cell cultures (Sims 
et al., 2012).  50 kDa xCT was detected in human glioma cells (Kim et al., 2001) and 
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retinal ganglion cell line membranes (Dun et al., 2006).  In vitro expression of xCT in 
Xenopus oocytes (Sato et al., 1999) and HT22 cells (Burdo et al., 2006) showed a band of 
an approximately 40 kDa protein, which could be downregulated by siRNA (Burdo et al., 
2006).  This 40 kDa xCT was detected in rat brain tissue, with the expression level 
increasing during development and reaching the highest expression as an adult (La Bella 
et al., 2007).  xCT was also observed in mouse hippocampus at a molecular weight of 
~35 kDa, which is absent in xCT -/- mice (Pacchioni et al., 2007; De Bundel et al., 2011).   
There are also studies reporting that xCT is detected at multiple molecular masses 
in the same tissue, with the same antibody.  A study done in primary rat astrocyte cultures 
revealed three distinct bands for xCT: 40, 45, and 50 kDa, however, only the 40 kDa was 
released from the system xC- heterodimer after reducing agent was added (Seib et al., 
2011).  xCT was also detected at 50 kDa and 40 kDa in mouse Muller cells, with the 50 
kDa protein as the majority version.  However, it was not inducible by oxidative stress, 
while the minority 40 kDa form, which is normally predominantly located intracellularly, 
was upregulated by oxidative stress and translocated to the membrane (Mysona et al., 
2009).  The same 40 kDa form of xCT was also found to be almost exclusively present on 
the cellular membrane in rat brain tissue, cultured human fibroblast, rat neurons and 
astrocytes (La Bella et al., 2007).  xCT was detected at 35 kDa and 55 kDa in mouse 
brain and mouse astrocyte cultures, with the 55 kDa form prominently detected only in 
mouse meninges (Shih et al., 2006).   
Together with these mixed results, there are also a number of system xC- studies 
that did not report the band(s) mass in their paper (Bridges et al., 2004; Qiang et al., 
2004; Sakakura et al., 2007).  It seems that the use of different antibodies and different 
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tissues can lead to different results.  Furthermore, increased expression does not 
necessarily mean increased membrane expression and increased function.  Therefore, 
claims about potential system xC- function by measuring xCT protein expression must be 
considered skeptically.  In our studies, we have focused on the functional activity of 
system xC- measured by 14C-cystine uptake.   
 
Relevance and limitations of translating in vitro studies to in vivo:  
 It has been suggested that when compared to in vivo, system xC- activity is much 
higher in vitro (Lewerenz et al., 2012).  This is believed to be because system xC- activity 
can be easily induced.  Even regular cell culture conditions with ambient O2 of 21% 
strongly induces system xC- activity in diverse cell types, including fibroblasts, HEK 
cells, hippocampal HT22 cells, astrocytes, and microglial (Lewerenz et al., 2012).  In 
freshly prepared hepatocytes and macrophages, the activity of system xC- is barely 
detectable (Takada and Bannai, 1984; Watanabe and Bannai, 1987), but it is significantly 
upregulated after 12 hours of culturing (Watanabe and Bannai, 1987).  A much higher 
system xC- activity level is measured in macrophages cultured for 8 hours in the presence 
of LPS and diethyl maleate (Sato et al., 1995a).  Various electrophilic agents and 
different pH have been proven to be system xC- activity inducers (Reynolds et al., 1991; 
Sasaki et al., 2002).  These concerns regarding cell culture studies must be kept in mind 
when attempting to extrapolate cell culture studies to the in vivo situation.   
 Our in vitro data showed that astrocytes have greater system xC- activity than 
neurons (Lobner, 2009), in agreement with another lab (Jackman et al., 2012).  
Preliminary data from our lab indicates that neuronal conditioned media significantly 
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increases astrocytic system xC- activity within 24 hours (Fig. 5.7.).  The exact mechanism 
of how neuronal conditioned media causes this functional increase of system xC- in 
astrocytes requires further study.   
 
 
FIGURE 5.7.  24 hour exposure to neuronal-conditioned media (NCM) increases 
system xC- mediated cystine uptake in astrocytes. 
Culture media from the DIV 13 primary mouse glia-enriched cultures was replaced with 
NCM collected from DIV 13 neuronal-enriched cultures, 14C-cystine uptake for 20 min is 
measured 24 hours later.  Bars show % control (mean ± s.e.m., n = 12-16). * indicates 
significantly different from control uptake.   
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CONCLUSION 
System xC- dysregulation has been implicated in various neurodegenerative 
diseases and psychiatric disorders.  The dual function of system xC- awards it a distinct 
role in influencing cell fate.  It may be protective by promoting cystine uptake and 
preventing oxidative stress, but it may be harmful by releasing glutamate and 
exacerbating excitotoxicity.   
The goal of this thesis was to add to the knowledge regarding the role of system 
xC- in neuronal death.  Two major advancements to the field were made.  First, we 
discovered that the environmental neurotoxin BMAA acts as a substrate for system xC-.  
Through this action, BMAA both inhibits cystine uptake, leading to oxidative stress and 
drives glutamate release causing excitotoxicity.  This result is important not only for 
understanding the mechanism of BMAA toxicity, but also provides evidence that 
compounds that are transported by system xC-, particularly if they do not lead to 
increased glutathione production, are potentially highly neurotoxic.  Second, the results 
involving FGF-2 suggest that increasing system xC- selectively on astrocytes is 
potentially harmful to neurons.  This finding, in concert with the well known neurotoxic 
action of glomas, that also have upregulated system xC-, suggests a general hypothesis 
that upregulation of system xC- on non-neuronal cells can be toxic to neurons.   
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